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Abstract 
Human embryonic stem cells (hESCs) are an invaluable tool for studying human embryonic development 
and have great potential for drug development as well as cell replacement therapies. Progress in hESC 
research is greatly hindered by the difficulty of generating genetically modified hESC lines. Recently the 
clustered regularly interspaced short palindromic repeat- (CRISPR) CRISPR-associated 9 (Cas9) system from 
Streptococcus pyogenes was shown to facilitate genetic engineering, but its applicability in gene targeting 
with long donor templates in hESCs has not been demonstrated, yet. The main objective of this study was 
to develop a strategy for rapid production of faithful hPSC fluorescent reporter lines.  
hESCs were targeted upstream to the stop codons of the pluripotency transcription factors NANOG and 
OCT4 to generate NANOG-VENUS (NV) and OCT4-mCHERRY (OC) reporter lines expressing NV and OC fusion 
proteins, respectively. Homologous recombination was facilitated by targeting a site proximal to the 
insertion site with RNA-guided nucleases or double nickases. Furthermore the strategy involved the use of 
short homology arms to allow employing customizable synthetic DNA blocks and a promoter trap approach 
for positive selection to increase the targeting efficiency. 
The strategy allowed rapid and robust production of hESC reporter lines with high targeting efficiencies, 
though a double reporter line could not be derived in a single targeting step. In the NV reporter VENUS 
faithfully reflected NANOG expression, but further analyses are required to confirm the precision of the OC 
reporter. Despite low qualities of the CRISPR targets, mutations were only detected in a single off-target 
locus that was completely homologous to the target. However, at the on-target sites concomitant mutations 
were observed that could be prevented in the targeted allele by mutating the protospacer adjacent motif 
sequences in the homology arms.  
In conclusion, the CRISPR-Cas9 tool from S. pyogenes is a simple and highly efficient tool that facilitates 
gene targeting using long donor templates. It is recommended to locate CRISPR target sites outside coding 
regions or regulatory elements to avoid potentially confounding mutations at the target site. 
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Resumé 
Humane embryonale stamceller (hESC) er et værdifuldt model for den humane embryonale udvikling og har 
et stort potentiale i lægemiddeludviklingen samt behandlingen af degenerative sygdomme. Fremskridt i 
hESC forskning er hindret af, at det er svært at udføre genetiske studier på hESC. Clustered regularly 
interspaced short palindromic repeat- (CRISPR) CRISPR-associated 9- (Cas9) systemet fra Streptococcus 
pyogenes blev vist at gøre præcise genetiske modifikationer væsentligt lettere, men systemet blev endnu 
ikke testet i forbindelse med målrettede modifikationer af hESC ved hjælp af lange donor DNA sekvenser. 
Det primære mål med dette studie var at udvikle en strategi, der tillader hurtig produktion af præcise hESC 
fluorescerende rapporterlinjer, der kræver anvendelsen af lange donor sekvenser. 
hESC blev modificeret i 5´ siden af stopkoden af pluripotensfaktorerne NANOG og OCT4 for at genere 
NANOG-VENUS (NV) og OCT4-mCHERRY (OC) rapporterlinjer, der udtrykker henholdsvis NV og OC 
fusionsproteiner. Den homologe rekombinering blev fremmet af at målrette CRISPR-Cas9-systemet mod et 
sted tæt på stopkoderne. Desuden var det en del af strategien at bruge korte homologe arme, der muliggør 
anvendelsen af brugerdefinerbare syntetiske DNA blokke, og en promoter trap-baseret fremgangsmåde for 
positiv selektion med hensyn til at øge targeting effektiviteten. 
Den anvendte strategi muliggjorde hurtig produktion af hESC rapporterlinjer med høje targeting 
effektiviteter, der dog ikke var tilstrækkelig høje for deriveringen af en dobbelrapporterlinje i ét skridt. NV 
rapporterlinjen reflekterede NANOG ekspression nøjagtigt, men yderligere analyser er nødvendige for at 
bekræfte præcisionen af OC rapporteren. Til trods for den lave kvalitet af de anvendte CRISPR blev 
mutationer kun detekteret i ét off-target locus, der var komplet homologt til on-target sekvensen. Derimod 
blev der observeret mutationer ved on-target sekvenserne, der kunne forhindres i det modificerede allel 
ved at mutere protospacer adjacent motif sekvensen i de homologe arme. 
Det kan konkluderes, at CRISPR-Cas9-systemet fra S. pyogenes er et simpelt og effektivt værktøj, der 
fremmer målrettede modifikationer af hESC ved brugen af lange donor DNA sekvenser. Det anbefales at 
målrette CRISPR-Cas9-systemet mod sekvenser udenfor kodende regioner eller regulatoriske elementer for 
at undgå potentielt skadelige mutationer. 
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1. Introduction 
One of the great wonders of nature is that a single fertilized egg cell can give rise to an entire new organism. 
The basic principle of development is that complexity does not arise through a multitude of signals or 
options at any single time point, but rather through repeated branching of fates as a response to the same 
set of signals used repeatedly [1]. This principle is also known as sequential induction or modulated 
repetition. Despite this seemingly simple system, studying the mechanisms of embryonic development has 
kept developmental biologists occupied in decades and unravelling the details of lineage specification is still 
at the cutting edge of research. 
In model organisms such as nematodes, zebrafish, frogs, the chick and the mouse many universal processes 
of development have been unveiled. Despite the wealth of information gathered embryonic development is 
far from completely understood, and certainty about the processes of human development ultimately 
requires research in a human setting. 
Due to obvious ethical reasons human embryonic development cannot easily be studied. With the 
derivation of human embryonic stem cells (hESCs) in 1998, an in vitro model for studying human embryonic 
development was formed [2]. hESCs are pluripotent stem cells (PSCs) that can be derived from surplus in 
vitro fertilized egg cells. PSCs are characterized by self-renewability and the capacity to develop into cells of 
all three germ layers [2]. 
The potential of hESCs and the more recently derived human induced PSCs (hiPSCs) [3, 4] go far beyond 
being a model for embryonic development. Potentially indefinite numbers of mature cells, tissues or even 
organ-like structures can be derived from hPSCs and used in the context of cell replacement therapies, 
disease modelling, drug development and toxicology studies. Probably the most ground-breaking potential 
application of hPSCs is in regenerative medicine, where degenerative diseases such as type one and 
advanced stages of type two diabetes as well as Parkinson´s disease may be cured by transplanting hPSC-
derived mature cells.  
One of the main challenges for hPSC research is the derivation of sufficient quantities of pure and fully 
functional stably differentiated cells. Immense progress in the development of differentiation protocols has 
already fostered a multitude of preclinical studies using PSCs. For example in an animal model for diabetes, 
hyperglycaemia was relieved by transplantation of hESC-derived pancreatic progenitors [5], and an in vitro 
hiPSC-derived liver bud matured to a vascularised liver upon transplantation to ectopic locations in the 
mouse [6]. However, scaling up and standardizing differentiation protocols as well as maturing and isolating 
the desired cell type remain major hurdles for translation of hPSC research [7].  
The common approach to induce PSCs to become the cell type of interest is to recapitulate in vivo 
development. Differentiation protocols are usually inspired by findings from the development of model 
Introduction 
4 
 
organisms such as the mouse, but also depend on trial and error. To systematically optimize differentiation 
protocols, it is necessary to precisely understand each branching point in the lineage specification of the 
cells of interest, as well as the nature of hPSCs themselves. Or put in other words, a deeper understanding 
of human embryonic and foetal development would likely promote the field of regenerative medicine, and 
since the access to human foetal tissue is very limited, studies in hPSCs provide the best proxy. 
One of the most powerful tools to unravel the missing pieces in differentiation protocols are fluorescent 
reporter lines [8-10]. In reporter lines the fluorescence gene is expressed from the endogenous promoter of 
the gene of interest and, consequently, cells expressing the gene of interest are marked by fluorescence. 
The gene of interest usually is a key transcription factor that is essential for a distinct developmental stage 
and therefore, amongst other things, reporter lines allow purification of cells within a specific 
developmental stage based on fluorescence. Since differentiation of PSCs yields a heterogeneous mixture of 
cells [11], purification of cells being in the developmental stage of interest is crucially important for 
unambiguous analyses [8]. By replating the isolated cells a key question can be answered, namely which 
cells in the heterogeneous mixture of cells are the progenitors that give rise to the mature cells of interest 
[8].  
The production of hPSC fluorescent reporter lines is a tedious process that depends on the 
rare event of homologous recombination [12]. hPSCs are among the models in developmental biology, in 
which it traditionally have been difficult to target genes [9, 13]. The main objective of this study was to 
develop a highly efficient and timesaving strategy for the derivation of hESC reporter lines.  
It was previously shown that genetic engineering tools such as zinc finger nucleases (ZFNs) and transcription 
activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats 
(CRISPRs) facilitate gene targeting in hPSCs by increasing the efficiency of homologous recombination [14-
17]. Among the genetic engineering tools the newly developed CRISPR technology holds great advantages 
over ZFNs TALENs that depend on the time-consuming design and optimization of novel proteins [18]. In 
contrast the CRISPR components are rapidly assembled [19] and cuts in the deoxyribonucleic acid (DNA) can 
be induced simultaneously at several loci with a single protein, facilitating multiplexed genome 
modifications [20].  
The CRISPR-CRISPR-associated 9 (Cas9) system from Streptococcus pyogenes has already proven to facilitate 
efficient generation of fluorescent reporter mice [21] and homologous recombination using short donor 
templates in human transformed cell lines and hPSCs [14, 15], but there is limited knowledge on gene 
targeting using long donor templates in hPSCs [22].  
In this study NANOG-VENUS (NV) and octamer-binding transcription factor 4- (OCT4) 
mCHERRY (OC) reporter lines were efficiently derived, proving the practicability of using the CRISPR-Cas9 
Introduction 
5 
 
system from S. pyogenes for targeting large transgenes in hPSCs. NANOG and OCT4, also known as POU 
domain, class 5, transcription factor 1 (POU5F1), are key pluripotency transcriptions factors [23]  that are 
also proposed to play a role in the early endodermal lineage choice [24, 25]. An incitement to target 
pluripotency factors was their expression in hPSCs, which facilitated rapid production and characterization 
of the reporter lines. Additionally, the derived NV and OC reporter lines are valuable tools for studying the 
dynamics of NANOG and OCT4 in different states of pluripotency and early endodermal development. 
In the remaining paragraphs of the introduction the theoretical background for the study is 
described in more detail, with a focus on conveying the medical relevance and potential of hPSC basic 
research. An introduction to PSCs is given, focusing on the derivation, pluripotent nature and the potential 
applications of PSCs as well as remaining challenges in the PSC research field. Additionally, the production 
and applications of fluorescent reporter lines are outlined, the CRISPR-Cas9 system is discussed, and the 
role of OCT4 and NANOG in pluripotency is introduced.  
1.1. Human embryonic stem cells and human induced pluripotent 
stem cells 
1.1.1. Derivation and characteristics 
Pluripotency is defined by the combination of self-renewability and the capacity to differentiate into any cell 
type of all three germ layers. In contrast totipotency is defined as the ability to form cells from all three 
germ layers plus all extraembryonic cell types.  
The fertilized egg cell is totipotent and ESCs are derived at the preimplantation blastocyst stage of the 
embryo (Figure 1), when the cells of the embryo have lost totipotency. At the blastocyst stage the embryo 
consists of a fluid-filled sphere that is outlined by the cells of the trophectoderm, and contains the inner cell 
mass (ICM) in a corner of the blastocyst cavity (Figure 1). The extraembryonic trophectoderm will form the 
foetal part of the placenta, while the ICM already segregates into the extraembryonic hypoblast and the 
pluripotent epiblast [26]. The epiblast develops into the embryo. ESCs are derived by isolation of the ICM 
and derive from cells of the preimplantation epiblast [2, 27, 28]. The preimplantation blastocyst stage is in 
humans is reached 4.5 days post fertilization [2], but the highest hESC derivation rate has been achieved 
with day 6 embryos [29]. 
Mouse ESCs (mESCs) had already been derived almost 2 decades before hESCs [30, 31], and it had been 
shown that mESCs retain the capacity to integrate into the epiblast and contribute to the developing mouse 
[32]. Tetraploid chimera experiments have shown that mESCs alone can support complete foetal 
development [33], and tetraploid complementation is still the golden standard for assessing pluripotency of 
mESCs. However, due to ethical reasons pluripotency of hESCs cannot be tested by chimera experiments 
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and the less stringent teratoma-forming potential assay or in vitro differentiation must suffice [34]. In 
addition to functional assays, biochemical assays enable more quantitative comparisons of epiblast and 
different ESC line signatures [35]. Often expression of the core pluripotency factors NANOG, OCT4 and/or 
Sry-related HMG box 2 (SOX2) are used to confirm pluripotency of PSCs [36, 37]. 
Pluripotency is not a stable state in vivo, but it can be maintained indefinitely in vitro through pluripotency-
supporting culture conditions. Hence, pluripotency exists in versions that have different propensity for 
either self-renewal or differentiation. The difference between the preimplantation epiblast from the ICM 
and hESCs is underscored by varying transcriptional profiles [38]. Not only does the in vitro situation diverge 
from the in vivo situation, also different hESC lines diverge in their differentiation capacity and proliferation 
rate [39, 40]. Additionally, pluripotency is characterized by an intrinsic heterogeneity that was suggested to 
underlie the capacity of PSCs to respond to differentiation signals. This hypothesis is based on 
heterogeneous expression of pluripotency transcription factors such as Nanog within PSC populations, the 
interconvertible nature of the distinct expressional states, and the increased differentiation propensity of 
the low-expressing cells [41, 42].  
mESCs derived from certain mouse strains are in a more stable pluripotent state, termed naïve pluripotency 
that is characterized by decreased propensity for differentiation, more homogeneous expression of 
pluripotency transcription factors, X chromosome activation and the use of different enhancers for the 
regulation of Oct4 [34, 35, 37, 43]. mESCs from other mouse strains can be converted to naïve pluripotency 
by specific culture conditions [reviewed in 35] and, recently, culture conditions that support naïve 
pluripotency of hESCs have been identified [37, 43]. 
Though mESCs and hESCs are derived from preimplantation stages, hESCs are more reminiscent of mouse 
epiblast stem cells (mEpiSCs) that are derived from the postimplantation embryo and are in a state that is 
poised for differentiation, termed primed pluripotency [34, 44, 45]. Further similarities between mEpiSCs 
and hESCs are X chromosome inactivation and similar growth factor requirements for self-renewal. 
However, it is speculated that hESCs revert to a primed state due to inappropriate derivation and culture 
conditions [46].  
More recently iPSCs have been derived by reprogramming mature cells to a pluripotent state 
by forced expression of pluripotency factors (Figure 1)[3, 4, 47]. Reprogramming has a long history, and was 
achieved by somatic nuclear cell transfer in a frog [48]. Later transdifferentiation of various cell types to a 
myogenic fate was achieved by transformation with the master muscle transcription factor MyoD [49, 50]. 
hiPSCs generation were originally achieved with two different cocktails of 4 pluripotency factors transduced 
with retroviruses or lentiviruses [3, 4]. OCT4 and SOX2 were common, and additionally either KLF4 and 
cMYC, or NANOG and LIN28 were used. Later other combinations were successfully applied [51], and 
various different reprogramming strategies were developed [52]. hiPSCs have been derived by lipoaspiration 
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from adipose stem cells [53], by blood samples from a fraction of the blood [54], by  skin samples or 
plugging hair from fibroblasts and keratinocytes [55, 56]. Blood or skin samples are typically taken for 
generation of hiPSCs from patients [57]. 
hiPSCs are derived with low efficiency and reprogramming occurs to varying degrees [35]. Incompletely 
reprogrammed cells retain a memory of their origin and have a limited developmental potential. Hence 
characterization of several clones of a novel iPSC line is necessary to obtain fully reprogrammed hiPSCs. The 
fully reprogrammed hiPSCs are considered to be very similar to hESCs [35], though there is evidence that 
some memory of the source cell type remains in hiPSCs [58]. For miPSCs it has been demonstrated by 
tetraploid complementation that iPSCs can support foetal development [59]. Given the high degree of 
similarity between hESCs and hiPSCs, findings based on hESCs are relevant for hiPSC research as well, and 
vice versa. In fact, studies have used hiPSCs and hESCs in parallel giving the same results [8].  
Other hPSCs are human embryonic carcinoma cells and rather unstable human embryonic 
germ cells that have been derived from patients with teratocarcinomas or primordial germ cells, 
respectively [60, 61]. Finally, mesenchymal stem cells have pluripotent plasticity, but chimera experiments 
have shown that mesenchymal stem cells cannot form all adult cell lineages [62, 63]. Due to the 
requirement for transformation, the low stability or the limited developmental potential of these hPSCs the 
focus in this study is on the non-transformed, stable and fully pluripotent hESCs and hiPSCs. In the following 
the term hPSC refers to hESCs and hiPSCs.  
1.1.2. Potential applications 
The hPSC model has important advantages over previous systems. Small or large mammalian animals 
provide in vivo models that are very similar to the human system. However, the use of model animals is 
ethically controversial and costly. Importantly, there are differences between the development as well as 
cellular and organ morphology of the species [64, 65]. Hence, there is a need for a complementing human 
in vitro model. A wide range of human immortalized or cancer cell lines are available and they are usually 
cost-effective and timesaving. However, these cell lines contain mutations in key genes associated with cell 
proliferation and survival, and the clinical relevance of findings using those cell lines is often limited [66]. 
Finally, primary cells obtained from humans usually have a poor survival and/or change the expression of 
key metabolic genes in vitro [7, 67]. hPSCs are capable of self-renewal without immortalization and they 
have the potential to differentiate into all cell types of the adult body by recapitulating processes of the 
embryonic development. Therefore hPSCs have the potential to serve as a model for human embryonic 
development, and to be used in cell replacement therapies, disease modelling, drug development and 
toxicology studies (Figure 1) [68]. Advances in the translation of hPSC research to clinical applications are 
introduced in this section. Animal PSCs are relevant to test the safety and efficacy of hPSC applications in 
vivo in animal models. 
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Figure 1: Derivation and use of hPSCs. The schematic shows that hESCs- and hiPSCs-derived differentiated cells have immediate 
applications in disease modelling, pharmacological screening in toxicity tests. The first PSC line to be derived was human 
embryonic carcinoma cells (hECs). hiPSCs are derived via reprogramming cells, e.g. obtained by biopsies or blood samples of 
donors, and hESCs are derived from the blastocyst stage of the embryo. Both forward and reverse genetic analyses of genetic 
diseases can be performed. The cells for reverse genetic analyses are obtained from patients with a genetic disease or embryos 
that have undergone preimplantation genetic diagnosis (PGD). By genetic rescue of the disease-causing mutations proper 
isogenic controls for the studies are produced. Similarly, reverse genetics require gene modifications such as targeted mutations. 
The application of hiPSC- and hESC-derived cells in transplantation therapies requires rigorous safety testing and is not available, 
yet. Copied from [68]. 
A lot of progress was made in the development of hPSC differentiation protocols. Many cell 
types from various lineages resembling cells that exist in vivo can now be derived, including the hepatic 
[69], cardiovascular [70], hematopoietic [71], neural [72] and pancreatic lineages [10]. Additionally, three-
dimensional structures such as aspects of the retina, pituitary gland or the brain from mPSCs [73-75] and 
liver organ buds from hiPSCs have been produced in vitro [6]. These advances in the development of 
differentiation protocols have fostered a wealth of preclinical studies using hPSCs. 
 hPSCs were found to be applicable as models for genetic diseases, and this novel field is 
known as PSC-based disease modelling. Disease modelling deals with finding pathways that contribute to 
disease and may be targeted by drugs. Novel drugs need to be highly specific in order to exceed the efficacy 
of current drugs or have reduced side effects, and identifying molecular pathways underlying disease 
aetiology and progression may inspire drug design. Many animal disease models exist, but hPSCs-derived 
cells can act as a human model for disease. In order to study genetic diseases with hESCs and hiPSCs the 
cells need to carry a disease-causing genotype. Both forward and reverse genetic analyses are possible with 
hESCs and hiPSCs (Figure 1).  
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Before the appearance of hiPSCs reverse genetic analyses depended on the occurrence and the detection of 
genetic disorders at the in vitro fertilized oocyte stage. Preimplantation genetic diagnosis enabled the 
discovery of genetic disease at this stage [76], and hESC lines for several genetic disorders were derived, 
including cystic fibrosis, Huntington´s disease, fragile X syndrome, thalassamia, Duchenne and Becker 
muscular dystrophy, myotonic dystrophy and Fanconi anaemia [77-79]. However, the access to surplus in 
vitro fertilized egg cells is limited and only models for monogenic disorders or chromosomal abnormalities 
can be obtained with this method. In contrast, the derivation of hiPSCs from patients, e.g. with 
multifactorial or even non-inherited diseases, provides the possibility to establish disease models of 
diseases with complex aetiology and without the dependency on genetically abnormal embryos. hiPSCs 
have for instance been derived from patients with maturity onset diabetes of the young (MODY) [80, 81], 
type 1 diabetes [82], type 2 diabetes [83], amyotrophic lateral sclerosis [84], spinal muscular atrophy [85], 
Fanconi anaemia [86], familial dysautosomia [87], thalassaemia, sickle cell anaemia [88], Parkinson disease, 
Huntington disease and Down syndrome [reviewed in 89, 90]. 
The challenge for disease modelling is to generate systems in which a disease phenotype develops. A 
phenotype might be apparent already in hPSCs, become obvious during the differentiation, manifest in the 
mature cells that are affected by the disease or might require more complex set-ups. If the disease 
pathogenesis involves non-cell autonomous mechanisms, engineered biomaterials and other cell types may 
aid to model the in vivo context [91]. In vitro systems may be impractical to model diseases with long 
latencies or complex pathophysiology. In this case human-animal chimeras can provide means to study the 
disease-specific hiPSCs in a complex and changing environment [92, 93]. 
Additionally to define a disease phenotype a healthy wild-type control is of crucial importance. The best 
control for reverse genetic studies is an isogenic controls that is obtained by gene modifications of the 
disease-specific hPSC line to correct the genetic defect [57]. Isogenic controls are necessary since different 
hPSC lines were shown to have varying characteristics. For instance, several hiPSC lines derived from the 
same patient have different capacities to differentiate into insulin-producing beta-cell-like cells, likely due to 
the inherent variability in the reprogramming process [94, 95]. Hence, in this example using a different 
hiPSC line as control might lead to false conclusions on the effect of a genetic defect on the lineage 
specification of pancreatic ß-cells. Isogenic controls have the exact same genetic background and stem from 
the same hPSC line, and differences in the phenotype of hPSC-derived cells are therefore likely not 
confounded. However, for non-Mendelian genetic disorders or non-inherited diseases isogenic controls 
cannot be obtained, and hiPSCs from healthy individuals have to suffice. 
Disease phenotypes have been observed in, for instance, MODY-hiPSC derivates. hiPSCs derived from 
MODY2 patients were shown to have a reduced capacity to differentiate to insulin-secreting beta-cell-like 
cells [80]. MODY2 patients carry a mutation in the gene encoding glucokinase (GCK), and when the 
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mutation is corrected the isogenic control differentiates normally. Similarly hiPSCs from patients with 
Fanconi anaemia cannot differentiate into haematopoietic progenitors in contrast to the corrected isogenic 
control [86]. 
hiPSCs from a children with spinal muscular atrophy differentiated into motor neurons with distinct 
perturbations [85]. Spinal muscular atrophy is a genetic disease leading to infant mortality due to loss of 
motor neurons and subsequent muscle weakness. Additionally the responsiveness to the drug valproic acid 
was assessed and non-responsiveness was attributable to the increased expression of the fatty acid 
translocase CD36 [96]. 
Both hiPSCs from patients with familial or sporadic Alzheimer´s disease showed accumulation of amyloid-
beta-peptide (Aß), when they were differentiated to neurons or astrocytes [97]. Aß accumulation had 
divergent manifestations and responded differently to the drug docosahexaenoic acid. The study provided 
an explanation for the variability in drug response and indicated that the drug is effective for a subset of 
Alzheimer´s patients. The Alzheimer´s and spinal muscular atrophy examples show that PSC-based disease 
modelling could be used to define markers that would predict drug-responders versus non-responders. 
As an alternative to reverse genetics forward genetics enables the analysis of the effects of the perturbation 
of a gene modification. The first step in forward genetics is mutagenesis, for instance to perturb the 
expression of a known disease-causing gene [57]. An obvious disadvantage with forward genetics is the 
possibility of gene redundancy that could mask a disease-causing allele. 
An example of forward genetics is the production of a hESC-based model for Lesch-Nyhan syndrome that is 
caused by a mutation in the gene encoding hypoxanthine-guanine phosphoribosyltransferase (HPRT1) and 
lead to a uric acid accumulation in the blood associated with kidney problems and moderate intellectual 
disability [98]. HPRT1 was disrupted by gene targeting and in absence of a functional HPRT1 hESCs attained 
a distinct phenotype, including the increased production of uric acid. 
Mature cells derived from hPSCs may also serve as a model for pharmacological high-
throughput screening. Of special interest are models that reflect the phenotype of a disease, since the 
reversal of the disease phenotype would constitute a clear read-out. The previously mentioned examples of 
spinal muscular atrophy- and Alzheimer´s-specific hiPSCs have shown that drugs may act similarly in vivo as 
in cells derived from disease-specific hPSCs [85, 97].  
In toxicology research there is a need for improved systems to test the toxicity of potentially 
hazardous chemical compounds and early stage drug candidates. A Problem with current animal models is 
pharmacotoxicological differences between species which were shown to exist for, in example, thalidomide 
and 13-cis retinoic acid [99-101]. Only 11% of drug candidates entering clinical trials are registered and of 
those 23 % are retracted afterwards, and safety concerns are the reason for 30 % of the late attritions [102]. 
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The cost-savings associated with more reliable toxicology screening platforms would be immense. 
Additionally the number of animals needed in extensive projects poses ethical issues and comes with high 
costs. For instance the toxicity assessment of more than 30.000 chemicals under the Registration, 
Evaluation, Authorisation and Restriction of Chemicals (REACH) programme of the European Union was 
estimated to require 10 million experimental animals [103]. hPSCs was for instance suggested for the 
assessment of embryo, cardiac, hepatic, skin, and neural toxicity [reviewed in 7].  
In the embryotoxicity field the Embryonic Stem Cell Test (EST) is the only well-established in vitro test [104]. 
Toxicity of a compound was originally assessed by morphological alterations induced on beating 
cardiomyocytes produced in embryonic body differentiations from mESCs, as well as by cytotoxicity on 
undifferentiated mESCs and fibroblasts [105]. The test was shown to predict non-embryotoxic and weakly 
embryotoxic compounds with 78 % reliability and strongly embryotoxic compounds with 100% accuracy 
[106, 107]. To improve the predictive capability of the test, hESCs instead of mESCs have been used and 
molecular endpoints such as the flow cytometry-based assessment of stage-specific marker gene expression 
via the introduction of a reporter gene (FACS-EST) and automated proteomic and transcriptomic analysis 
have been proposed [7, 108-112]. Recently the European Centre for the Validation of Alternative Methods 
accepted the 10 day FACS-EST procedure as a method to assess embryotoxicity [113].  
Testing for cardio- and hepatotoxicity is critical in drug development, since many drug candidates have 
adverse effects on heart and liver [114, 115]. Several cell and tissue models exist for testing cardiac toxicity, 
but despite their sensitivity and usefulness for high-throughput screens they do not provide the human 
cardiac environment and may result in false positive results [116]. Primary human hepatocytes are the most 
suitable system to study drug metabolism and hepatotoxicity [reviewed in 117]. However, their ability to 
metabolize drugs decreases rapidly in culture and prolonged or repeated exposures to the drugs is often 
necessary to unravel toxic effects. Additionally hepatocyte activity from different donors varies and may 
confound the results. 
Cardio- and hepatotoxicity are among the main health safety concerns that cause late attritions of drug 
candidates or withdrawal of already approved drugs [7]. E.g. 298 drugs were recently identified that cause 
liver injury as a side effect [118] and the anti-inflammatory Vioxx that has been administered to more than 
80 million people is a prominent example for a withdrawn drug with cardiac side effects [119]. Hence, 
better models are necessary to increase the predictive capability of toxicity assessment. 
The potential usefulness of hPSC-derived cardiomyocytes and hepatocytes in safety pharmacology was 
shown in many studies [7, 120-124]. In example hESC-derived cardiomyocytes were comparable to mature 
cardiomyocytes in their reaction to drugs [125]. However, cardiotoxicity testing is hampered by the 
incomplete understanding of the molecular mechanisms underlying the toxic effects, which makes it 
difficult to devise appropriate endpoints for the studies. In hPSC-derived hepatocyte-like cells the presence 
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and functionality of enzymes associated with both phase I and phase II metabolism of drugs were partly 
determined [126-129]. The expression levels of key enzymes were shown to be highly heterogeneous and 
therefore a set of criteria to ensure the similarity of hPSC-derived hepatocytes to freshly derived primary 
human hepatocytes was proposed [130, 131].  
As yet, only proof of concept studies have been performed, and the superiority of using hPSCs-based 
strategies instead of the commonly used models in safety pharmacology are not shown [7].  
hPSC-derived cells can potentially be used for transplantation-based cell replacement 
treatments. The main vision of hPSCs in regenerative medicine is to derive cells or tissues from hPSCs to 
replace non-functional tissue. A long line of preclinical data suggests that hPSCs have potential as a cure for 
several diseases [reviewed in 132]. The studies are based on animal models of human disease and either 
autologous PSC transplantations into animals with a normal immune status or xenogeneic hESC 
transplantations to immunosuppressed or immunocompromised animals.  
hESC-derived pancreatic precursors were able to generate glucose-responsive insulin-secreting cells in vivo, 
a hall-mark of pancreatic beta cells that has not been achieved in vitro, yet [5, 64]. The transplanted cells 
were capable of alleviating streptozocin-induced hyperglycaemia [5]. 
Another report shows that miPSC-derived neural precursor cells transplanted to the mouse foetal brain 
migrated to various regions of the brain and differentiated to mature glial cells and neurons [72]. 
Additionally it was shown that miPSC-derived dopaminergic neurons reduced the symptoms of a rat model 
of Parkinson´s disease. 
Furthermore iPSCs obtained from mice with a humanized model of sickle-cell anaemia were genetically 
corrected, differentiated to haematopoietic progenitors and transplanted to the diseased mouse in an 
autologous manner [133]. Sickle-cell anaemia was rescued by the graft. 
miPSCs were also capable of saving mice with haemophilia A that were challenged by a tail-clip bleeding 
assay [71]. Mice grafted with miPSC-derived endothelial cells 7 to 90 days prior to the bleeding assay 
survived for more than 3 months. In contrast mice without transplants only survived few hours. 
Recently the generation of a vascularised and functional organ from hPSCs in a combination of in vitro 
differentiation and in vivo maturation was reported [6]. By co-culture of hiPSC-derived hepatocytes with 
endothelial cells and mesenchymal stem cells on a matrix a spherical liver bud was formed in vitro. The liver 
bud was grafed to three sites in immunodeficient mice and vascularised and functional liver-like organs 
formed at all sites. This study provides a human model of liver organogenesis and shows that hPSCs may 
eventually provide a treatment against liver failure.  
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To date no clinical trials with hPSCs have been completed. In 2010 a clinical trial transplanting hESCs as a 
treatment for severe spinal cord injuries was intiated [134]. The trial was interrupted in 2011, officially due 
to a change in the focus of the company towards cancer therapies [135]. Destruction of the spinal cord 
leads to paralysis of the lower limbs, and restoration of limb movement would be an accomplishment that 
justifies the risks and side effects associated with hESCs, which are introduced in the next paragraph.  
It was announced that this year the first clinical trial using hiPSCs as a treatment for age-related macular 
degeneration will be initiated [136]. Macular degeneration leads to defects of the retinal pigment 
epithelium of the eye. Cell injection and monitoring of the graft is convenient because of the easy access to 
the eye, and graft survival will likely be supported due to the immune-privileged character of the eye.  
A sign for the increased interest of pharmaceutical companies in hPSCs is that 45 % of the 20 biggest  
pharmaceutical companies have started engaging in hPSC research [137]. 
In summary, hPSCs have a three-fold role in drug development; disease modelling may 
unravel disease-specific pathways and inspire more target-oriented development of drugs, and 
pharmacological screens and toxicity assessment may become more precise with the access to non-
immortalized human cells or tissues. Furthermore preclinical data suggest that cell replacement therapies 
may provide a cure against conditions such as diabetes, haemophilia A, sickle-cell anaemia, Parkinson´s 
disease and liver failure. 
1.1.3. Challenges  
Though hPSCs may already be used as a model for embryonic development and to an increasing degree in 
drug development, many challenges remain for hPSC-based cell replacement therapies. Some of the 
challenges of hPSC research are presented in this paragraph.  
The use of hESCs raises ethical issues due to the destruction of an embryo during the derivation 
procedure. The fundamental question in the debate is whether or not a human life at the embryonic stage 
should be granted the moral status of a human being. The ethical concerns can be alleviated somehow by 
using surplus in vitro fertilized egg cells that would have been discarded. Since the embryo awaited certain 
death, research is not the reason for the death [138]. Since iPSCs are derived from adult cells and do not 
require the destruction of an embryo, it is less controversial to use hiPSCs than hESCs. Due to the ethical 
objections hPSC research has been haltered by political restrictions and regulations [139]. The public 
perception of the stem cell research is of importance for political decisions. The public attitude is now 
relatively positive and educating the public about, for instance, research regulations could further promote 
the public opinion [140].  
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Despite progress in optimizing hPSC culture conditions and developing efficient 
differentiation protocols, safe derivation of sufficient quantities of fully mature cells still constitutes one of 
the major hurdles for the translation to the clinic. 
The optimal culture condition for hPSCs would be chemically defined, free of xenogeneic components and 
allows for clonal long-term culture without generating chromosomal or genetic abnormalities [141]. hPSCs 
were as a standard cultured on mitotically inactivated feeder cells or matrigel and the medium was feeder 
cell-conditioned or supplemented with animal sera [2, 142-144]. hPSCs are anchorage-dependent and the 
feeder cells such as mouse embryonic fibroblasts (MEFs) support self-renewal and cell adhesion by the 
secretion of essential growth factors, cytokines and extracellular matrix (ECM) components [145]. Matrigel 
is derived from Engelbreth-Holm-Swarm mouse saracomas and also contain growth factors and ECM 
components [146]. However, the validity of mechanistic studies using these substrates and conditioned or 
serum-supplemented medium is limited due to the chemically undefined nature of these components 
[141]. Mitotic inactivation of feeder cells also renders them apoptotic and alters the level of secreted 
factors, and thereby introduces heterogeneity in hPSC culture [147]. Both animal and human biological 
components are subject to batch-to-batch variations and a source for contamination with infectious agents 
such as Mycoplasma species [148, 149]. Furthermore xenogeneic components may induce immune 
reactions, e.g. immunogenic sialic acid were reported to be secreted by MEFs [150]. MEFs and animal sera 
are still widely used.  
Partly chemically defined, feeder-free and xenogeneic component-free culture systems have been 
developed that allow clonal survival of hPSCs [151-153]. In these systems synthetic polymers or extra-
cellular matrix components support the delicate hPSCs, and single-cell passaging is supported normally by 
the addition of p160-Rho-associated coiled-coil kinase (ROCK) inhibitor, but other apoptosis inhibitors or 
chemically undefined substances have also been used [154-157]. As discussed further in the next section 
clonal survival of hPSCs is necessary for the capability to expand a single genetically modified cell to a novel 
cell line. However, ROCK inhibitor affects the cytoskeleton through perturbation of actin-myosin 
contractility [154], and the cytoskeleton is a mediator between signalling pathways and mechanical cues 
from the microenvironment [158]. A recently developed system used the stem-cell niche-associated ECM 
components laminin and Ecadherin and chemically defined medium [159]. The system allowed for single-
cell passaging without ROCK inhibitor and clonal derivation of hESCs without the generation of 
chromosomal abnormalities in long-term culture. A switch to chemically defined culture conditions allows 
more accurately assessment of the molecular basis of hPSC self-renewal and differentiation [141]. 
The production of high cell numbers for cell replacement therapies is labour-intensive with two-
dimensional culture systems and may be facilitated by three-dimensional cell-suspension culture systems, 
referred to as bioreactors [160]. hPSCs normally spontaneously differentiate and form embryoid bodies, 
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when they detach from the substrate. However, with appropriate culture medium large-scale expansion of 
hPSCs in bioreactors allow approxiamately four-fold and two-fold higher proliferation rates than feeder-
dependent and feeder free culture systems, respectively [161-163]. A suspension-based large-scale 
production of pancreatic precursor cells, a potential source for pancreatic ß-cells, has been reported [164]. 
The most intuitive and commonly used approach to induce PSCs to become the cell type of interest is to 
recapitulate in vivo development. In differentiation protocols PSCs are directed to go through the events of 
embryonic development by sequential exposure to signalling molecules. However, in general only a subset 
of cells differentiates into the desired cell type, which usually only acquire full functionality during 
maturation in vivo [5]. 
The lacking ability to produce fully functional cells in vitro is problematic for disease modelling, 
pharmacological screens and toxicity testing. For these applications models are needed that closely 
resemble the in vivo situation, and therefore fully matured cells are preferable. However, in the context of 
cell replacement therapy it is not clarified, whether transplantation of progenitors or fully mature cells will 
be more efficient and it may vary in different cell systems [64].  
A complicating factor is that hPSC lines vary in their capacity for differentiation, which limits the generality 
of the findings based on a single cell line [39]. Similarly differences between hPSC lines complicate 
standardization of differentiation protocols that would facilitate comparisons of different studies and thus 
accelerate clinical translation of the basic research. The underlying mechanisms are only partly understood. 
It was shown that the capacity of differentiation to different lineages varies during the cell cycle [165], and 
differences between hPSC lines in cell cycle progression may account for the heterogeneity in differentiation 
propensity [166]. The differentiation towards a certain germ layer could be controlled by manipulating the 
cell cycle with a small synthetic molecule [165]. Manipulation of cell cycle proteins may not only hold the 
key to decrease the heterogeneity between hPSC lines but also help to synchronize cells in the 
differentiation process. In differentiation protocols one of the problems is that the timing of differentiation 
in cells within a culture varies. E.g. in order to obtain the highest possible differentiation efficiency the 
differentiation factors in the medium may need to be changed before all cells have reached the 
developmental stage that is induced with the former factors. Hence, synchronizing the differentiation 
process would likely increase the differentiation efficiency.  
In addition to the differences between hPSC lines there is also an inherent heterogeneity within hPSCs 
A reason for immature phenotypes and low differentiation efficiencies may be insufficient knowledge on 
human embryonic development and culture techniques. Since access to human foetuses is limited, the 
growth factor cocktails added to the culture medium in differentiation protocols are mainly inferred from 
rodent development as well as from growth factor and small synthetic molecule screens [64, 167]. Hence, 
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the development of differentiation protocols is limited by differences in mouse and human development 
and depends on the chance that appropriate combinations of factors are found in screens. The 
differentiation factor cocktails used in current protocols may still be incomplete.  
Furthermore the comparatively short time span of differentiation protocols, usually around 1-3 weeks, 
might contribute to immature phenotypes of hPSC-derived cells. It was for instance found that some 
pluripotency factors remain after differentiation into cells of all three germ lines [168]. The expression 
patterns of the derived cells were comparable to those from foetuses 6 weeks post fertilization. Though the 
study does not provide evidence that the time frame of the differentiation protocol causes the immature 
phenotype, the issue of immature phenotypes is stressed. Also the study indicates that immature 
phenotypes not simply are in vitro artefacts, since the expression patterns have a counterpart in the human 
foetus. 
In culture it is difficult to reproduce the changing microenvironments that are characteristic of the dynamic 
embryonic development. While soluble factors can be added and removed with the culture medium, 
changing non-soluble clues such as transient cell-cell interactions or mechanical stresses are not easily 
mimicked. As previously mentioned, co-culture with endothelial cells and mesenchymal stem cells allowed 
the formation of a liver bud [6], and it might have been the proximity to certain other cells that allowed the 
success. A role of mechanical forces in development is increasingly recognized [169]. For instance in the 
haematopoietic system fluid shear stress increases the efficiency of haematopoietic colony-forming 
potential both in vivo and in hPSC differentiation [170].  
For cell replacement therapies it will be of crucial importance to exclude pluripotent cells 
from the transplant. If pluripotent cells remain in the culture or cells retain the capacity to dedifferentiate 
to a pluripotent state, transplants will potentially form teratomas [2]. Teratogenecity is the major safety 
concern with the use of hPSCs. In order to reduce the risk for teratogenesis hPSC-derived cell population 
could be sorted. E.g. systems based on fluorescence-activated cell sorting (FACS) have been devised to 
exploit the expression of cell-stage specific cell surface markers to isolate the cell type of interest. By 
isolating a primitive gut population after 6 days of culture based on three cell surface markers it was shown 
that the cells at this stage had lost their capacity to form teratocarcinomas and were restricted to the 
endodermal fate [8]. In contrast in the non-sorted population cells with teratogenic capacity remained.  
There are various other safety concerns linked to hPSC-based therapeutics, most of which are 
associated with the derivation of iPSCs. The initial reprogramming strategy employs retroviruses or 
lentiviruses and the transduction of oncogenes such as OCT4 and c-Myc. Already before the derivation of 
iPSCs it had been shown that retrovirus vector insertion can lead to premalignant cell proliferation [171] 
and overexpression of OCT4 to dysplasia by inhibiting cellular differentiation [172]. A part of the problem 
was solved by omitting c-MYC or exchanging it for L-Myc [51, 173]. Thereby the tumorigenecity in iPSC-
Introduction 
17 
 
derived mice were reduced. Furthermore the possibility to derive transgene insertion-free iPSCs have been 
explored intensively, e.g. with the use of chemical compounds [174, 175], adenovirus transfection [176], 
transposons [177, 178], plasmids and various vectors [179-181], recombinant proteins [182, 183], modified 
ribonucleic acid (RNA) [184], and microRNA [175]. However, still some of the original reprogramming factors 
needed to be transduced, the reprogramming efficiency was low and/or incomplete reprogramming was 
observed with the strategies. 
The variety in the reprogramming efficiency of hiPSCs is another issue. It seems as if some cell types are 
more permissive for reprogramming than others, and some iPSCs retain expression of socalled 
reprogramming-resistant genes [52]. In regard to safety concerns especially tumor-promoting 
reprogramming-resistant genes are problematic. Also it is not certain whether epigenetic memory of the 
previous cell type remains and can affect the differentiantion process and/or the functionality of the iPSC-
derived cells [185].  
The optimal reprogramming strategy would allow the derivation of completely recombined hiPSCs without 
the use of stably and randomly integrating vectors. However, there is still no such optimal way for the 
derivation of hiPSCs [52], and at the moment hESCs are probably the safer option for development of cell 
replacement therapies. 
It has to be pointed out that both hiPSCs and hESCs progressively acquire genetic and chromosomal 
aberrations in prolonged culture [186, 187]. E.g. the 20q11.21 region is frequently duplicated and provides 
a selective advantage via enhancing proliferation and inhibiting apoptosis [188]. 
 In transplantation therapies hESCs would need to be transplanted in an allogeneic fashion, as a non-
self transplant. Since hESCs have been found to be immunogenic [189], immunosuppressive drug regimens 
are likely required to accompany cell replacement therapies to prevent rejection of the transplant. Due to 
the lack of clinical studies with hESCs, the degree of their immunogenicity is not known. As yet it needs to 
be expected that the situation is similar as in organ transplantations, where immunosuppressive 
therapeutic regimens with severe side effects are administered [190]. Hence, the applications of hESCs are 
restricted to diseases that are more severe than the side effects of the immunosuppressive drugs. 
To minimize immune reactions in cell replacement therapies a hESC bank with high diversity in the human 
leukocyte antigen (HLA) signatures would be necessary. Based on assumptions used for heart or kidney 
transplantations it was calculated that a bank of 150 hESC lines would only provide a full match at HLA-A, 
HLA-B, and HLA-DR for 20 % or a HLA-DR match for 85 % of the population in the United Kingdom [191]. 
However, it is not sure whether hESC immunogenicity follows the same rules as organ transplantations.  
With the appearance of hiPSCs the prospect of patient-specific hPSCs and the in vitro production of 
autologous self-transplants arose. Since hiPSCs can be obtained from the patient, subsequently 
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differentiated and transplanted hiPSC-derived cells were initially not expected to induce immune reactions. 
However, a recent study questions whether autologous iPSC really are non-immunogenic. Autologous 
miPSCs have evoked immune rejection, when non-differentiated iPSCs, but not when thoroughly 
characterized non-differentiated iPSCs or predifferentiated iPSC-derived cells were transplanted [192]. Non-
differentiated mESC derived from the same inbred mouse strain did not induce immune reactions. It was 
hypothesized that the immunogenicity are caused by abnormal expression of antigens that might arise due 
to subtle epigenetic and genetic abnormalities of iPSCs [192]. Further studies are needed to clarify whether 
allogeneic iPSCs are immunogenic. A study in primates indicates that autografts are less immunogenic than 
allografts [193]. Future studies need to validate that patient-specific iPSCs are advantageous to justify their 
use instead of the more cost- and time-effective allogeneic hiPSCs or hESCs for developing hPSC-based 
therapeutics [194]. Furthermore autologous hiPSCs might carry a genotype that causes the disease, which is 
obvious in monogenetic diseases and less certain in multifactorial diseases. The use of hiPSCs from patients 
with congenital disease would be precluded unless the disease-causing mutation is corrected. 
An avenue for the derivation of patient-specific hPSCs other than hiPSCs was recently found. Somatic cell 
nuclear transfer to enucleated human oocytes succeeded, the oocyte matured to the blastocyst stage and 
hESCs were derived [195, 196]. Some first evidence indicates that reprogramming of the somatic cells with 
this strategy is less problematic than with the iPSC technology [197]. Further research is needed to confirm 
the functionality and safety of these nuclear transfer-derived hESCs. 
Other hurdles are related to the complications that come along with the introduction of a 
complete new area of therapies. In order to translate the basic research into the clinics, rules and 
regulations for patents, hPSC culture and safety testing need to be defined, and practical issues such as the 
development of surgical procedures and cell delivery systems must be solved [134, 198]. 
A critical and unsolved issue is how to test for the safety and efficacy of hPSC-based cell therapy preclinically 
[52]. In contrast to most drugs that are metabolized relatively fast, hPSC therapy is an irreversible 
intervention. Therefore confirmation of the safety of hPSC-derived grafts is of particular importance. The 
capacity for differentiation towards various lineages could be a minimal safety requirement. However, 
differentiation protocols are likely tolerant to subtle epigenetic and genetic aberrations or subtle 
abnormalities in gene expression [52]. The best models to test toxicity and teratoma-forming potential are 
probably large animals [198]. 
 In summary, many basic aspects of hPSC research require further studies. Due to limited access to 
human foetal tissue, progress in the hPSC field will likely be guided by animal models, but also by trial and 
error using hPSCs as a model. In order to realize the full potential of the hPSC model, hPSCs must be 
genetically modified, in example to produce fluorescent reporter lines. In fact, a major technical bottleneck 
has been the inefficiency of gene targeting in hPSCs.  
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1.2. Human pluripotent stem cell fluorescent reporter lines  
1.2.1. Production  
In a fluorescent reporter line an autofluorescent protein is expressed from a cell type-specific promoter. 
Fluorescent proteins are commonly derivatives of green fluorescent protein (GFP) originally isolated from 
the jellyfish Aequorea Victoria [199]. GFP has similar spectral characheristics as fluorescein (FITC), but is less 
cytotoxic [200]. Examples of GFP derivatives are enhanced GFP (eGFP) that contains a mutation enabling 
folding in 37°C [201], and its slightly red-shifted derivate VENUS [202] with excitation peaks at 488 nm and 
514 nm, respectively. Their safety and applicability has also been confirmed in vivo [203]. Red fluorescent 
proteins (RFP) was isolated from mushroom corals, from Discosoma species, and a  more photostable and 
less toxic RFP derivative is monomer CHERRY (mCHERRY) that has its excitation peak at 587 nm [204]. Due 
to their different spectral characteristics RFPs and GFPs can be expressed and detected in the same cell.  
The approaches to producing stably transfected hPSC reporter lines can be divided into 2 
major groups, depending on whether a random or targeted integration of the transgene is achieved. 
In the random integration strategy the promoter of the gene of interest is cloned upstream of the reporter 
gene, and the reporter construct randomly integrates into the genome [205-207]. Among the random 
integration strategies transduction of cells with lentiviruses is the preferred approach due to their relatively 
stable expression and efficiency of transduction and random integration [208].  
A disadvantage with the random integration strategy is that the transgene might be inserted into a gene. In 
particular with the use of lentiviruses disruption of a gene occurs frequently due to the preference of 
lentiviruses for integrating in active genes [209]. Another important drawback is the possibility of position 
effects. The transgene might be inserted into densely compacted heterochromatin, and become silenced or 
comparatively less expressed than the endogenous gene due to propagation of the epigenetic signature of 
the locus [210]. Gene disruption, silencing and variations in transgene expression can be circumvented by 
recombinase-mediated cassette exchange or the phiC31 integrase system that allows insertions into 
transcriptionally active sites such as the ROSA26 or the pseudo-attp locus, respectively [211, 212].  Finally, 
the cloned promoter fragment might lack some important enhancer elements that are further up- or 
downstream. Bacterial artificial chromosomes (BACs) harbour extensive regions up- and downstream of the 
gene of interest and increase the probability that all regulatory factors associated with the endogenous 
locus are included [213]. A pitfall associated with BACs is the possibility for ectopic expression of other 
genes present in the BAC.  
In the gene targeting approach the transgene is inserted into a specific site in the gene of interest by 
homologous recombination. Homologous recombination is an intrinsic property of cells and occurs during 
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the homology-directed DNA repair pathway (HDR) [1]. HDR depends on the availability of sister chromatids 
as a template for precise DNA repair. In gene targeting homologous recombination depends on homology 
arms (HAs) flanking the reporter construct (Figure 2). The length of the HA is associated with both relative 
and absolute targeting efficiency in that longer HAs facilitates homologous recombination, but not random 
integration [12, 208]. Long HAs can be recovered from BACs.  
 
Figure 2: Schematic of homologous recombination. A reporter cassette (grey) can be targeted to a specific genomic site (between 
A and B) by cloning A as 5´ HA upstream and B as 3´ HA downstream of the reporter cassette. Homologous recombination 
enables the integration of the transgene into the genome. In a fluorescent reporter line the main components of the reporter 
cassette are usually a fluorescence gene (C) and an antibiotic resistance gene (D). 
The transgene can be targeted to any part of the gene and insertion may be accompanied by the excision of 
a part of the gene [208]. When the transgene is inserted in the coding sequence, it has to be inserted in the 
reading frame for proper expression. Insertion at the 5´ end of the gene usually is at the start codon and the 
transgene will be expressed instead of the endogenous gene and use an exogenous polyadenylation signal 
to terminate the transcript [8]. Disruption of an allele is not an option, when the gene is haploinsufficient. 
The transgene may also be inserted in the 3´ end of the gene in front of the stop codon in order to produce 
a fusion protein [17]. An obvious pitfall of this strategy is the possibility that fusion to the transgene could 
perturb the function of the targeted protein. When a fusion protein is not desired, insertion into the 3´ 
untranslated region (UTR) remains an option [12]. With the use of an internal ribosomal entry site (IRES) or 
2A self-cleaving peptide, multicistronic expression have been achieved in hPSCs [214]. 
Genetic engineering tools such as ZFNs and TALENs have proven to increase the efficiency of gene targeting 
in hPSCs by several orders of magnitude [16, 17, 215, 216]. ZFNs and TALENs contain a non-specific Fok1 
cleavage domain fused to specificity conferring zinc finger or TALE repeat domains, respectively. The 
advantage of the newer TALEN genetic engineering tool is the decrease in context-dependent effects 
between its domains, which facilitates the design of TALEN proteins [217] and permits to target virtually any 
DNA sequence [218]. The biology underlying the increase in efficiency is the ability of ZFNs and TALENs to 
specifically cut the DNA at the desired integration site. The DNA repair machinery is alerted by the DNA 
damage and the reporter cassette is integrated by HDR. 
The gene targeting approach is considered superior to random integration, since the epigenetic and 
regulatory genomic environment is more fully preserved in gene targeting [208].  
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Reporter cassettes are integrated into the genome with a low efficiency. To facilitate positive 
selection of genetically modified hPSC clones, an antibiotic resistance gene is included in reporter 
constructs. Positive selection strategies have been difficult to establish in hPSCs due to their poor survival at 
low densities and as single cells. The use ROCK inhibitor has significantly improved the cloning efficiency 
[155], but clonal survival of hPSCs is still low and cell-line specific [219, 220]. The antibiotic resistance gene 
is normally constitutively expressed from an exogenous promoter. It is the consensus in the field that the 
exogenous promoter should be removed once genetically modified clones have been obtained [208]. E.g. 
excision of the selection cassette were efficiently achieved by flanking the cassette with loxp sites, known as 
`floxing´, and expression of the Cre recombinase [8]. The removal is thought to prevent interference of the 
exogenous promoter with expression from the close-by endogenous promoter due to competition for 
transcription factors and/or steric hindrance [208]. Alternatively, the selection marker may be expressed 
from the endogenous promoter, referred to as a promoter trap [208]. This strategy is limited to making 
reporters of genes transcribed in hPSCs, since the promoter driving the transcription of the gene for the 
selection marker must be activate to allow positive selection. 
Another important issue in the production of reporter lines is the delivery of the reporter 
plasmid to the cell. Like the positive selection, the delivery method turned out to be a technical bottleneck 
for the derivation of reporters [12, 208]. As mentioned before, lentiviruses have proven to offer the highest 
efficiency [221-223], and nucleofection was shown to be superior to conventional electroporation and 
lipofection [223, 224]. It is possible that the performance of the delivery systems varies in different PSC 
lines, and optimizations of the delivery system remain crucial for efficient production of reporter lines. 
The technology used for the production of reporter lines is transferable to other applications, 
where transgenes need to be inserted. For instance the ectopic expression of key developmental genes to 
affect differentiation or the removal of a gene to produce a knock-out model may be achieved using the 
same tool kit. 
1.2.1. Applications 
The ability to identify and isolate hPSC-derived progenitors or mature cells holds the key to develop 
differentiation protocols and fully exploit the potential of hPSCs. Reporter lines enable to follow cells live 
and allow convenient isolation of cells based on the expression of the fluorescent marker. Fluorescent 
reporter lines have several advantages over alternative systems for the analysis, identification and isolation 
of specific hPSC-derived populations [208, 225]. Gene tags such as beta-galactosidase can only be detected 
after fixation or exposure to specific substrates, while fluorescent reporters can be viewed live under the 
fluorescence microscope [226]. This allows researchers to follow the dynamics of single cells within a 
population or cultured alone, which is particularly valuable for heterogeneous populations such as hPSCs or 
hPSC-derived cells [227]. By combining fluorochromes with varying spectral characteristics several 
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molecular properties can be probed and even quantified simultaneously. The advantages to follow single 
cells in live-imaging encompass the ability to reveal heterogeneity that may be obscured by population 
averages, and to determine the dynamics of expression unambiguously (Figure 3).  
Another important application of reporter lines is the sorting of heterogeneous population of cells, e.g. by 
flow cytometry based on the expression of a fluorescent protein. This is crucially important for 
unambiguous analyses of the heterogeneous hPSC-derived populations. E.g. cell type-specific cell surface 
markers can be determined by comparative expression microarrays [8]. The cell-type specific cell surface 
markers may subsequently be used to isolate non-genetically modified hPSC-derived populations used for 
cell replacement therapies. Similarly, cells expressing antibiotic resistance genes under the control of the 
promoter of interest have been enriched by drug selection [228] and tags also allow for purification of 
marked cells. However, proteins conferring antibiotic resistance are not as easily monitored and quantified 
as autofluorescent proteins, and other cell types produced during the differentiation cannot be analyzed 
[208]. Importantly, gene tags do not allow reculturing of cells after isolation. The possibility to reculture 
cells after purification enables determination of the developmental potential of isolated cells. This is for 
example useful to ensure that no teratoma-forming potential remains [8], or that a certain transient 
developmental stage gives rise to the clinical relevant cell type [229].  
In summary, stable fluorescent reporter lines for several prominent factors in the embryonic development 
have been produced and greatly promoted progress in the PSC research field [8, 10]. However, though a 
wide range of approaches to derive hPSC reporter cell lines have been explored, the production of hPSC  
Figure 3: Live-cell imaging using 
fluorescent reporter lines can unravel 
molecular cell fate control. Fluorescent 
reporter lines can be followed 
continuously under fluorescent 
microscopes and thereby reveal 
heterogeneity in a population that may be 
hidden behind population averages (a). 
Furthermore the cell fate (b) and 
molecular behaviour (c) may be 
determined nonambiguously (cells carry a 
reporter for two genes shown by red and 
blue). Copied from [227]. 
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reporter still requires considerable time and effort. The possibility to rapidly derive faithful reporter lines 
would greatly encourage the derivation of novel reporter lines, and the CRISPR-Cas9 system is an interesting 
candidate for increasing the efficiency of hPSC reporter production. 
1.3. CRISPR-Cas9 system 
1.3.1. The CRISPR-Cas system underlies adaptive immunity of bacteria and 
archeae 
The CRISPR-Cas9 tool is derived from an adaptive immune system that exists in a wide range of bacteria and 
archaea [230-232]. The CRISPR-Cas adaptive immune system consists of a genomic DNA element, the 
CRISPR cluster, and Cas proteins. The CRISPR cluster contains repeats of 2 elements that each are around 
24-37 bp long [233]. The elements are short repetitive sequences and unique spacer sequences that are 
often derived from viral genomes during previous infections [234]. In subsequent infections the CRISPR 
cluster is transcribed to CRISPR RNAs (crRNAs) that can direct Cas endonucleases to sequences in the viral 
DNA that are homologous to the spacer sequences [231]. The viral DNA will be digested and the viral 
infection is fended off. Hence, the CRISPR-Cas system provides immunity by a genomic memory of previous 
infections.  
There are three different types of CRISPR-Cas systems, and in type I and III sytems multiprotein complexes 
are necessary to induce the degradation of the viral DNA [235]. In the type II system, the Cas9 protein solely 
depends on an RNA duplex to be directed to the foreign DNA and is thought to induce a blunt end double-
strand break [236, 237]. The RNA duplex consists of the crRNA that recognize the viral target DNA by 
Watson-Crick base-pairing and the transacting crRNA (tracrRNA) that binds both the pre-crRNA and 
provides a scaffold for the Cas9 protein to bind [236, 237]. The pre-crRNA is cleaved by the bacterial 
ribonuclease III upon binding the tracrRNA [237]. 
1.3.2. Generation of a genetic engineering tool from the type II CRISPR-
Cas9 system  
It was quickly realized that the CRISPR-Cas system was programmable to cut various DNA sites [236]. Due to 
the simplicity of the underlying Watson-Crick base-pairing between the RNA and its target it possessed 
great potential as genetic engineering tool. In contrast, the previous meganucleases, ZNF and TALEN tools 
recognize the target DNA by interactions of a protein with the DNA. Hence, producing the RNA-guided 
CRISPR system only requires insertion of the target sequence in the directing RNA [19], while the protein-
guided meganuclease, ZFN or TALEN system necessitates the time-consuming design, testing and 
optimization of proteins [18, 238]. Put differently, while a protein needs to be designed for each target in 
protein-directed systems, the protein remains the same for different targets in the CRISPR-Cas system. 
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To keep the system as simple as possible, focus has been on developing a type II-based CRISPR-Cas tool that 
would only necessitate the use of one protein. Further simplifying the system the crRNA and tracrRNA was 
fused, and the resulting small guide RNA (gRNA) showed to be more efficient in directing the Cas nuclease 
as the crRNA-tracrRNA duplex [15, 19]. 
The vast majority of studies have used the CRISPR-Cas9 system derived from S. pyogenes, and it is therefore 
the best characterized CRISPR-Cas9 system [239]. However, studies using Cas9 proteins from S. 
thermophillus or Neisseria meningitides have shown to be feasible and to extend the targeting range of the 
CRISPR-Cas9 system [19, 22, 240]. 
A requirement for the Cas9 nuclease to cut the target DNA is the protospacer adjacent motif (PAM) that lies 
adjacent to the target sequence (Figure 4) [234]. Hence, the targeting range of the CRISPR-Cas9 system is 
dependent on the existence of a PAM site, which in the case of S. pyogenes Cas9 is NGG. In average a GG 
motif occurs every 8th nucleotide in the genome, and it is therefore theoretically possible to target almost 
any sequence. Additionally the targeting range is increased in that NAG or NNGG motifs can serve as 
alternative PAM sites, though resulting in a lower cutting efficiency [236, 241].  
Different Cas9 variants have been engineered to increase the applicability of the CRISPR-Cas9 system. Wild 
type (wt) Cas9 has two active sites, and each site is responsible for cutting one of the complementary DNA 
strands [242]. The active sites cooperatively induce a double-strand break approximately 3 bp upstream of 
the PAM sequence between bp 3 and 4 in the spacer sequence [236]. The double-strand break can either be 
repaired by the non-homologous end-joining (NHEJ) or HDR (Figure 4). The error-prone NHEJ is the 
common pathway and usually induces small deletion or insertion mutations (indels), or point mutations 
[239, 243]. The cleavage and mutagenesis efficiency of the CRISPR-Cas9 system has been found to be equal 
to or greater than the efficiency of TALENs or ZFNs [239, 244]. 
The balance between NHEJ and HDR can be slightly shifted towards HDR by providing a donor template [14, 
15, 245]. By including a transgene within the donor template, gene targeting can be achieved. In the 
production of fluorescent reporter lines the donor template is the reporter cassette flanked by HAs.  
Through the introduction of the D10A or H840A mutations Cas9 nickases (Cas9n) have been produced that 
cut the DNA strand which is complementary or homologous to the spacer sequence, respectively [236, 246, 
247]. Nicking the DNA can be an advantage, if mutations in the targeted DNA are not desired. Alternatively, 
both active sites can be inactived, and the system converts from a DNA cutting tool into a catalytically 
inactive DNA targeting tool [236, 248]. Effector proteins can be targeted to a specific genomic locus by the 
gRNA, for instance, via fusion to Cas9. 
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Figure 4: CRISPR-Cas9 target recognition and double-strand break repair pathways. The engineered CRISPR-Cas9 system from 
S.pyogenes contains two components, the specificity-conferring gRNA and the Cas9 endonuclease (A). The gRNA contains a 
sequence that is complementary to the genomic target (blue Ns) and provides a scaffold for the Cas9 proteins. Through Watson-
Crick basepairing with the complementary sequence in the genome the gRNA directs the Cas9 nuclease to the genomic target 
and a double-strand break is induced approximately 3 bp upstream of the NGG PAM sequence. Theoretically the only genomic 
sequence requirement for the system is the PAM sequence that is necessary for the nuclease activity. The induced double-strand 
break can either be repaired by error-prone NHEJ or precise HDR (B). NHEJ results in indels of variable lengths. When a donor 
template is provided HDR can be exploited for the generation of insertions or modifications via homologous recombination. 
Modified from [249] and [239]. 
1.3.3. Low targeting specificity is a major concern 
As for other genetic engineering tools off-target effects have also been observed for the CRISPR-Cas9 
system. The specificity of the CRISPR system is conferred by the around 20 bp spacer and the PAM sequence 
and in the large mammalian genomes many potential off-targets may exist.  
Multiple studies have assessed the specificity of the CRISPR-Cas9 system [241, 250-252], and 
some principles governing the targeting specificity as well as options to reduce off-target effects have been 
found. However, there have also been considerable differences in the findings and clear rules underlying the 
targeting specificity could not be derived. Additionally, consensus on how to assess off-target activities in 
studies using the CRISPR-Cas9 technology has not been reached [239]. 
The number of mismatches to the target sequence that were shown to be tolerated ranged from 1-5 [241, 
250-252]. In general the cleavage efficiency is reduced by mismatches, but occasionally the cleavage 
efficiency is even increased in the presence of a mismatch. The distal 8 bp of the target sequence tolerate 
more mismatches than the PAM sequence and the 12 bp `seed´ region proximal to the PAM sequence. 
Mismatches within the seed or PAM sequence usually block nuclease activity [19, 236, 251]. However, NAG 
and NNGG PAM sequences may be used alternatively and mismatches in the seed sequence are no 
guaranty against off-target effects [236, 251]. An alarming finding is that excessive off-target activity might 
lead to genomic instability [253, 254]. 
Reducing the concentrations of the CRISPR components might affect the ratio of on-target to off-target 
activity. One study shows a proportionate reduction in on- and off-target activity [250] while another finds a 
relatively larger decrease in off-target cleavage [251].  
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A Cas9n-based strategy was developed in order to reduce off-target effects. Cas9n-induced nicks will usually 
be repaired faithfully and not result in mutations, though mutations occur sporadically [14, 15, 252, 255]. 
Mutations are probably the consequence of stalled replication forks that induce double-strand breaks at the 
site of the nick [256]. By using two gRNAs with target sequences on the opposite strands that are optimally 
0-20 bp apart (off-set), a double-strand break-like lesion with  5´ overhangs are induced at the target site 
(Figure 5) [14, 257]. Double-strand breaks at off-target sites are unlikely due to the low probability that off-
target sites for the CRISPRs are in proximity of each other. 
  The previously mentioned targeting range is practically considerably lower than every 8th 
nucleotide due to the need of reducing off-target effects. The theoretical possibility to use any PAM 
sequence in the genome is limited by the uniqueness of the adjacent targeting sequence. Off-target effects 
can more or less certainly be excluded, when the target seed sequence or PAM sequence has several 
mismatches to any other genomic sequences [241, 250-252]. It is probably not as relevant for research 
applications as for therapeutic applications to ensure the lack of off-target effects, and even CRISPR with a 
perfect match at other genomic loci can be eligible for research-based studies [21]. Hence, depending on 
the specificity requirements of the study, the `actual´ targeting range and thereby the applicability of the 
CRISPR-Cas9 system may be limited. 
 
Figure 5: Schematic of CRISPR off-target effects with the nuclease and double nickase strategies. The specificity of the CRISPR-
Cas9 system is conferred via gRNAs that often recognize off-target sites in addition to the on-target site. The nuclease strategy 
induces double-strand breaks at on- target sites, and error-prone DNA repair mechanisms result in mutations (A). If off-target 
sites are recognized as well unwanted mutations are created. The double nickase strategy supposedly reduces the off-target 
effects, while maintaining a high on-target activity (B). The double nickase strategy requires two gRNAs with target sequences  in 
close proximity on each strand of the complementary DNA strands (red and blue arrow) to produce a double-strand break-like 
lesion. When off-target sites are recognized, single-stranded lesions called nicks are produced that are usually faithfully repaired. 
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Freely available web-based CRISPR design software such as the ZiFiT Targeter (zifit.partners.org) and the 
CRISPR Design Tool (crispr.mit.edu) help to evaluate CRISPR target sites within a user defined region of a 
specific genome. The tools score off-targets with algorithms that are based upon experimental data [251, 
255, 258]. These tools greatly facilitate the design of CRISPRs.  
1.3.4. A powerful tool for biological research  
After the generation of the CRISPR-Cas9 tool, it was quickly adopted by many researchers. In 2013 the 
feasibility of altering genes with CRISPR-Cas9 were shown in bacteria [259], transformed human cell lines 
and hPSC lines [15, 19, 260], yeast [249], tobacco [261, 262], thale cress [261], rice [263, 264], wheat [263], 
sorghum [265], mice [20, 21], rats [266], rabbits [267], zebrafish [258], frogs [268], fruit flies [269, 270], 
silkworms [271] and roundworms [272]. The CRISPR-Cas9 tool has a broad range of applications; in addition 
to gene disruption, addition and correction applications facilitated by targeted DNA cuts, gene activation 
and repression can be achieved with a catalytically inactive Cas9. 
The most obvious application of the CRISPR-Cas9 system is probably the production of 
knockout models. The highly efficient induction of indels at the target site through error-prone NHEJ usually 
results in the disruption of both targeted alleles due to premature stop codons. Up to 5 alleles have been 
targeted simultaneously [20]. The possibility to perform multiple genome alterations simultaneously can 
save time, for example, when several redundant genes of one family need to be knocked out. There are also 
several reports of CRISPR-based screens that use gRNA lentiviral libraries to produce libraries of cells with 
knockout mutations [272-275]. Forward genetic screens have been performed with both positive and 
negative selection mechanisms. In contrast to the incomplete knockout obtained in RNAi-based screens due 
to interference with the transcript, the knockout in CRISPR-Cas9-based screens is complete, since the 
alterations occur on the DNA level and therefore affect every transcript. Finally, by inducing two double-
strand breaks with 2 gRNAs targeting the same DNA molecule a deletion of the intermediate sequence can 
be obtained, e.g. posing an alternative route for production of knockout models [21].  
As previously mentioned, HDR can be exploited for gene targeting. Both insertion of large 
constructs, for instance containing a reporter gene and a drug selection cassette, and gene editing have 
thereby been performed with high efficiencies. In this thesis gene editing refers to the targeted 
modification of a few basepairs with short donor templates, e.g. to correct or induce a point mutation. 
Nanog-mCHERRY and Oct4-GFP reporter mice and mESC lines have been produced by co-injection of mouse 
zygotes with Cas9 mRNA and gRNA [21]. Around 75 % of the injected zygotes developed to blastocysts, and 
the targeting efficiency in the blastocysts were 9 % and 18 %, respectively. Furthermore, 4 out of 6 derived 
Nanog-mCHERRY mESCs lines uniformly expressed mCHERRY, while the remaining 2 showed mosaic 
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expression of mCHERRY. Mosaic expression of the transgene is the result of recombination events occurring 
later than the zygote stage.  
Positive selection becomes obsolete in that system, since recombined clones can be obtained by genetic 
screening of a moderate number of clones. If comparable targeting efficiencies could be reached in hPSCs, 
the positive selection cassette could be omitted in repoter constructs. Since the selection cassette usually 
needs to be excised subsequent to the selection process, omitting the selection cassette from the start 
would spare a lot of time in the production of reporter lines.  
In the transformed human embryonic kidney 293 (HEK293) cell line it was achieved to target large 
transgenes to both alleles of an essential gene simultaneously [276]. The transgenes contained different 
antibiotic selection mechanisms allowing the selection of clones, in which both alleles had been targeted. 
Though the absolute targeting efficiency was not stated in the study, it must have been sufficiently high to 
allow two simultaneous homologous recombination events in a single cell. This proofs the concept that 
multiplexed gene targeting is possible with the CRISPR-Cas9 system. It however, remains to be shown, 
whether multiplexed gene targeting is feasible in hPSCs as well. 
Gene editing with the CRISPR-Cas9 system does not require long donor templates. In hPSCs gene editing 
efficiencies above 1 % are typically achieved with short single-stranded oligos [14]. Multiplexed gene editing 
has been achieved by co-injection of mouse zygotes with Cas9 mRNA, mulitple gRNAs and donor templates 
[20]. Gene editing can be used to induce or to correct disease-causing mutations and is an important 
element in the previously discussed disease modelling. In addition to the research applications gene editing 
has potential for correcting the mutations in genetic diseases. As a proof of concept the CRISPR-Cas9 tool 
was applied to cure the genetic disease causing cataracts in mice [277]. Furthermore intestinal stem cells 
obtained from patients with cystic fibrosis were corrected the functionality of the corrected gene was 
confirmed in intestinal organoids [278]. 
However, before therapeutic applications may become a reality the target specificity of the CRISPR-Cas9 
system needs to be clearly defined and increased. Additionally, it is a major problem that NHEJ is the 
predominant pathway. While the homologous recombination event could correct the disease-causing 
mutation in one allele, the non-targeted allele will likely be mutated as well. To avoid indels it is necessary 
to shift the balance from NHEJ to HDR. By using a single nickase the balance could be shifted towards the 
HDR, but for most gRNAs at the price of decreased recombination efficiencies [14, 15, 19]. In addition to the 
wide variation in recombination efficiencies, some single nickases also efficiently induced mutations [14, 
252, 255]. Hence, further studies assessing the rules behind the observed differences between single 
nickases are needed. 
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Another potential application of the CRISPR-Cas9 system with considerable ecological and economical 
impact is within the modification of crops by gene editing or inserting longer transgenes [265]. 
Finally, the CRISPR-Cas9 system has been converted to a DNA targeting tool by mutating the 
active site of Cas9, resulting in a `dead´ Cas9 (dCas9) [236, 246]. By fusing the dCas9 to an activation domain 
or a repression domain and targeting the fusion protein to promoter regions by 1 or several gRNAs, efficient 
activation or suppression of transcription have been achieved [248, 279-281]. In hPSCs the cell fate of 
differentiating cells were shown to be effectible by changing the expression of key developmental genes 
[282].  
In summary, the CRISPR-Cas9 technology has only been developed in the past years, but 
already has become a mainstream method with interesting applications within research, crop refinement 
and potentially curing genetic diseases. However, the feasibility of increasing the efficiency of hPSC reporter 
production with the CRISPR-Cas9 system from S. pyogenes has not been explored [22]. In this study NANOG 
and OCT4 are targeted with fluorescence genes in hESCs to assess the practicability of targeting large 
transgenes with CRISPR-Cas9 in hPSCs.  
1.4. OCT4 and NANOG are core pluripotency transcription factors 
In PSCs pluripotency is largely governed by a conserved core transcription factor network, containing OCT4, 
NANOG and SOX2. The self-renewable pluripotent state is controlled by the combination of the core 
transcriptional network and an extracellular environment that favours expression of these transcription 
factors [283]. OCT4 and NANOG were identified as key pluripotency factors due to their unique expression 
pattern in ESCs, and genetic experiments confirmed their function in maintenance of a robust pluripotent 
state [284-286]. Though NANOG is dispensable in PSCs, the stability of the undifferentiated state is strongly 
decreased in its absence [41]. OCT4 and SOX2 act as heterodimer, and are generally required for 
reprogramming [3, 4]. NANOG, OCT4 and SOX2 co-occupy many enhancer sites throughout the genome 
[287] and are considered to be at the core of pluripotent transcriptional regulation [reviewd in 23]. They are 
estimated to positively regulate 64 % of the transcribed genes in pluripotency and repress cell lineage-
specific genes [287-290].  
However, the exact regulation of the core regulatory network is unclear. In example, the interdependency of 
the factors is disputed. It was suggested that the core pluripotency factors regulate themselves through 
positive feedback [291-293]. This autoregulation was further proposed to be the basis for the bistable 
pluripotent state, where self-renewal occurs in the presence of OCT4, NANOG and SOX2 and differentiation 
is initiated when any of the core pluripotency factors is lost. In contrast other studies suggested that 
NANOG is autorepressive and has little effect on OCT4 and SOX2 [294, 295]. 
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The changes in the regulatory circuit underlying the switch from the heterogenous primed to the more 
homogenous naïve pluripotency are controversial as well. NANOG expression is heterogeneous in primed 
pluripotency, but switches to a uniform expression in naïve pluripotency-supporting culture conditions [283, 
296-298]. Allelic regulation of NANOG was proposed as the cause for the differences in NANOG expression 
levels and the switch from primed to naïve pluripotency [299]. By targeting both alleles of NANOG without 
disrupting the coding sequence of the endogenous protein in mESCs it was shown that 80 % and 30 % of the 
cells monoallelically expressed Nanog in primed and naïve pluripotency, respectively. The finding confirmed 
in vivo data showing monoallelic expression of Nanog in the early embryo [299]. However, two studies with 
similar Nanog reporter designs in mESCs found biallelic expression of Nanog [296, 300]. In one of the 
studies the only deviation in reporter design was that the antibiotic selection cassette was excised [300] in 
contrast to continued expression of the antibiotic marker from the endogenous promoter via an IRES 
sequence [299]. The additional physical distance of 3.3 kb between the promoter and downstream 
enhancer sites [300] or decreased stability of the endogenous mRNA due to the IRES sequence [301] 
provide possible explanations for the contrasting findings. These studies highlight that even PSC reporter 
lines with similar designs may have divergent dynamics and lead to opposite interpretations. Additionally, in 
contrast to previous reports it was found that Nanog was not more heterogeneously expressed than other 
pluripotency transcription factors.  
Interestingly, in addition to their role in safe-guarding and specifying pluripotency, NANOG 
and OCT4 were suggested to be implicated in the early specification of the endoderm lineage [24, 25]. It 
was proposed that OCT4 switches its partner during endoderm development; when SOX2 expression is 
downregulated in early endoderm differentiation, OCT4 dimerizes with SOX17 [25]. SOX17 is a key regulator 
of definitive endoderm (DE), and OCT4 may enable activation of endoderm-specific genes by partnering 
with SOX17. In accordance with this hypothesis is the finding that enhanced endoderm and decreased 
ectoderm differentiation propensity was observed upon OCT4 overexpression [302]. The same study 
showed repression of neural and little effect on mesendodermal differentiation by NANOG overexpression. 
Furthermore suppression of NANOG facilitated differentiation towards pancreatic endoderm [303]. In 
conflict with these results is the finding that NANOG and not OCT4 is necessary for the activation of 
EOMESDERMIN (EOMES), which in turn activates the early DE transcriptional network [24].  
In summary, the regulatory circuitry underlying the bistability of pluripotency and the 
conversion of primed to more stable naïve pluripotency are still not completely understood. Fluorescent 
reporter lines for OCT4 and NANOG facilitate pluripotency research in that the fluorescence marker can 
serve as a proxy for the undifferentiated state [36, 37, 220, 284-286]. Furthermore the reporters could be 
used to investigate the role of NANOG and OCT4 dynamics in the conversion of primed to naïve 
pluriplotency. A double reporter for NANOG and OCT4 could be produced and elucidate the relation 
between these factors. The function and regulation of NANOG and OCT4 in pluripotency and early 
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mesendodermal development can be studied, in example by sorting of hPSCs or differentiating hPSCs based 
on OCT4 or NANOG expression levels and subsequent analyses of the isolated populations.
Methods 
32 
 
2. Methods 
2.1 Cell lines and cell culture 
The hESC lines H9 (WiCell Research Institute), SA-121 (Cellartis AB), HuES15 and HuES4 (both Howard 
Hughes Medical Institute) employed in this study were derived from surplus in vitro fertilized egg cells as 
previously described [2, 304]; details on the SA-121 line are available on the European Human Pluripotent 
Stem Cell Registry. All experiments with hESCs were performed between passages 28 and 70.  
The SOX17-GFP reporter gene construct was inserted in the H9, SA-121 and HuES15 lines. The NV and OC 
constructs were inserted to the HuES4 cell line. Wt H9 and HuES4 cells were used as controls for the 
reporter cell lines, and wt HuES4 cells were employed to test DE cell surface markers. The transformed 
HEK293 cell line was used for testing the CRISPR-Cas9 system.  
All hESC lines were grown on irradiated MEFs in hESC medium and passaged in a subconfluent state with 
Stem Pro Accutase (Life Technologies), except wt H9 cells which was split with Collagenase (Sigma). hESC 
medium was composed of KnockOut Dulbecco´s Modified Eagle Medium (KO-DMEM), 15% KnockOut Serum 
Replacement, 1% GlutaMax, 1% Minimum Essential Medium Nonessential Amino Acids, 0.1% ß-
Mercaptoethanol (all Life Technologies) and 10nM basic fibroblast growth factor (bFGF; PepreoTech) and 
sterilized by filtration after mixing the ingredients. The hESC media was stored at 4°C and discarded after 1 
month. bFGF was added freshly to the hESC medium or maximally stored for 3 days at 4°C. 
HEK293 cells were grown in DMEM with GlutaMax (Life Technologies) supplemented with 10% Foetal 
Bovine Serum (FBS; Sigma). 
2.1.1. Seeding mouse embryonic fibroblasts and human embryonic stem 
cells 
The culture dishes were coated with 0.1 % gelatine and incubated at 37°C for at least 10 minutes. MEFs 
were stored at -170°C or -80°C in Nunc Cryo Tubes, thawed in the hand, immediately transferred to 5 ml 
pre-warmed MEF medium, and centrifuged at 500 g for 3-5 minutes. The MEFs were seeded in MEF 
medium at a density of 2x104 cells per cm2 dish surface. 1 or 2 days after seeding the MEFs, hESCs were 
plated on the MEFs at a density of approximately 4-5x104 cells per cm2 dish surface in 0.2-0.3 ml hESC 
medium per cm2 dish surface. The medium was changed to fresh hESC medium on the second day after 
plating and every following day.  
Seeding of MEFs on 96-well plates was performed differently. 1 million MEFs were suspended in 5 ml hESC 
medium without bfgf and 50 µl cell suspension was added to each well. 1 or 2 days later and 6 hours prior 
to seeding hESC(s) 50 µl of hESC medium containing 20 µM Y-27632, also known as Rock inhibitor, 40 ng/ml 
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bFGF, and 2x Pen Strep (100 units/ml penicillin and 100 µg/ml Streptomycin) (Life Technologies) were added 
to each well of the 96-well plates. The 96-well plates have low evaporation lids. 
2.1.2. Passaging human embryonic stem cells and HEK293 cells 
hESCs were passaged on average every 3-4 days when they were 70-90 % confluent. Usually HuES15 cells 
were split 1:3 and the other hESC lines 1:4. The cells were washed with Dulbecco´s Phosphate Buffered 
Saline without MgCl2 and CaCl2 (PBS-/-) (Life Technologies), 25-60 µl Accutase per cm2 dish surface was 
added (more volume per area is needed for the smaller plates in order to cover the bottom of the well), and 
incubated 2-3 minutes at 37°C. The cells were washed off and dissociated to small clusters with hESC 
medium by carefully pipetting up and down a few times, and plated as described above.  Cells were counted 
with a Scepter Handheld Automated Cell Counter (Milipore) to ensure consistent cell seeding densities. 
HEK293 cells were passaged 1:10 with 0.05 % trypsin-EDTA (Life Technologies) when they were confluent, 
usually every third day. The cells were carefully washed with PBS-/- and incubated with 300 µl 0.25 % trypsin 
at 37°C for 1 minute. The cells were washed off the well with HEK293 medium, centrifuged and 
resuspended in MEF medium. 
2.1.3. Thawing and freezing human embryonic stem cells 
Cells were harvested as described above. The cells were centrifuged and subsequently resuspended in hESC 
medium containing 10 % dimethyl sulfoxide (DMSO). Typically 0.5-2 x106 cells were filled in each cryo tube 
in a 1 ml volume. The cryo tubes were directly transferred to a freezing box (Thermo Scientific), which was 
precooled to -20°C.  
When thawing hESCs the cryo tubes were thawn in the hand or in warm water, immediately transferred to 5 
ml prewarmed hESC medium, centrifuged 2-3 minutes at 300 g, resuspended in hESC medium and plated 
on the culture dish.  
2.1.4. Testing for Mycoplasma contamination 
The cells were at least passaged once after thawing and left without medium change for 2 days. 
Subsequently 1 ml of medium was withdrawn from the well and the EZ-PCR Mycoplasma Test Kit (Biological 
Industries) was employed following the manufacturer´s protocol. 
2.1.5. Definitive endoderm differentiation 
hESCs were differentiated to DE in essence following the D´Amour protocol [305]. When approximately 80-
90 % confluency was reached the cells were washed with PBS+/+ and the medium was changed to Roswell 
Park Memorial Institute Medium 1640 (RPMI) (Life Technologies) with 25ng/ml wingless-related integration 
site 3a (Wnt3a; R&D) and 100 ng/ml Activin A (PeproTech). The following day the cells were washed with 
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PBS+/+ and the medium was changed to RPMI with 100ng/ml Activin A and 0.2% FBS or 1x B27 Supplement 
(Life Technologies). This medium was maintained for 2 to 4 days with daily media changes. 
2.1.6. Positive selection of and expanding reporter cells 
Homologously recombined NV and OC clones are resistant against Hygromycin and Neomycin, respectively. 
Selection with hESC medium containing 100µg/ml Hygromycin B (Merck Millipore), 100µg/ml G418 (Life 
Technologies) or 50µg/ml Hygromycin B and 100µg/ml G418 was commenced 2-3 days after transfection. 
DR4MEFs (ATCC, #SCRC-1045) were used as feeder cells due to their resistance against Hygromycin and 
Neomycin. The concentration of 100µg/ml G418 was previously used in the lab [220] and the concentration 
of 100 µg/ml Hygromycin was experimentally shown to kill wt HuES4 cells seeded on DR4MEFs within 4 
days. However, the concentration was decreased to 50 µg/ml after 5 days of selection, since the DR4MEFs 
died quicker and the appearing NV colonies were smaller than the OC colonies selected with G418. 7 days 
after transfection DR4MEFs were reseeded. 
Selection was continued 9-12 days until 6 hours prior to picking the resistant clones, when the medium was 
changed hESC medium with 10 µM ROCK inhibitor. The medium was finally changed to PBS-/- and colonies 
were picked under a dissection microscope by excising them from the surrounding MEFs and sucking them 
up with 20 µl fine pipette tips. The cells were transferred to 10 µl Accutase, incubated for 2-5 minutes at RT 
and transferred to a well of a 96-well plate. The 96-well plates were preseeded with DR4MEFs and 2 days 
after transfering the clones the positive selection was resumed and half media changes were performed 
every second day.  
Sequentially the cells were split to 1 well of a 48-, 24-, and to 2 wells of a 12-well plate. Either the clones 
were further expanded to 6-well plates or 1 of the 2 wells of the 12-well plate was frozen and the other was 
harvested for genomic DNA extraction with the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma) 
following the Manufacturer´s protocol. Positive selection was stopped in the 48-well format. 
2.2. Polymerase chain reaction 
T100 Thermal Cyclers (BioRad) were used for thermocycling. In general the highly processive polymerase 
Elongase (Life technologies) was used for polymerase chain reaction (PCR) products above 4kb, while 
Phusion (Bionordika, M0531L) was the polymerase of choice for PCR products under 4kb. The 
manufacturers´ recommendations were followed, except for adding 5% DMSO to PCRs with Elongase. Also 
one minute elongation per kb product was applied for genomic DNA amplifications with Phusion. 
Annealing temperatures of primers were calculated with NEB´s Tm calculator and IDT´s Oligo Analyzer 3.1 
tools for PCRs using Phusion and Elongase, respectively. Primers were chosen with NCBI´s Primer-BLAST tool 
or by visual inspection of the DNA sequence to be analyzed. In general primer with 50-60 % G/C-content 
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with a length of around 20 bp were chosen. The primers used for amplification of the on- and off-target 
regions of the applied CRISPRs are 25 bp in lengths to increase the specificity of the PCR. All primers are 
listed in Table 1. 
Agarose gel electrophoresis was performed with 0.01 % SYBR Safe DNA Gel Stain (Life Technologies). Images 
were taken with the Molecular Imager GelDoc XR+ (BioRad) and edited with the Image Lab software. 
Table 1: Primer used for PCR reactions. In bold font are primer overhangs that are complementary to the adjacent reporter 
plasmid fragments; Abbreviations: Seq – sequencing; p – plasmid. 
Nr Sequence (5´-3´) Name  Purpose 
1 CCTGGTGAACCGCATCGAGC GFP-F Genotyping SG 
2 CTTGATGTGTGTGCTTGAGG SOXDws3HA-R  
3 GACCTTGGGCAAGTACGTCG SOXProm-F1 Seq SG  
4 GCGTATTGGCCCCAATGG DwsLoxP-R  
5 CAGGCAAGTTGAGTCCTGGG SOXProm-F2  
6 TTTATGTTTCAGGTTCAGGG DwsGFP-R  
7 GTAAAACGACGGCCAG M13-F Seq TOPO inserts 
8 CAGGAAACAGCTATGAC M13-R  
9 GATCCCTTCAAAGCTTGCCCTTGTCACCC Oct5HA-F pOC fragments 
10 GCCGCTACCGCCACTACCTCCGTTTGAATGCATGGGAGAGCC Oct5HA-R  
11 GGCTAGGGATAACAGGGTAATGAATGAATCACCGATACGC pBROct-F  
12 GCAAGCTTTGAAGGGATCCTCTAGAGTCGAGCAGTGT pBROct-F  
13 GGTAGTGGCGGTAGCGGCAGCGGTAG mCh/Ven-F (+ pNV fragment) 
14 TCAGAAGAACTCGTCAAGAAGGCG mCh-R1  
15 AAGGAATAGTGAAGATGAGTGAAACTGATATTACTCAA Nan3HA-F pNV fragments 
16 GATTCATTCGCAGTACTCATGTCATTACGATG Nan3HA-R  
17 GAGTACTGCGAATGAATCACCGATACGCGAG pBRNan-F  
18 TTTATTCCTGAAGGGATCCTCTAGAGTCGAGCAGTGT pBRNan-F  
19 TCATCTTCACTATTCCTTTGCCCTCGGA Ven-R1  
20 GTTGCTCAGGTCGCAGAC pBR-R1 Seq OC 
21 CTGTTGTGCCCAGTCATAG Neo-R1  
22 GATGGCCATGTTATCCTCC mCh-R2  
23 CTCACCCTCATCTTCGAC pBR-R2 (+Seq NV) 
24 GGAAATGTGCGCGGAAC pBR-R3 (+Seq NV) 
25 GGTATCATTGCAGCACTGG pBR-R4 (+Seq NV) 
26 GGATGGGCATCATGGAAATC Nan3HA-R1 Seq NV 
27 GCAGTACTCATGTCATTACGATG Nan3HA-R2  
28 GATCAGCAATCGCGCATATG Hyg-R  
29 CTTGAAGTTGGCCTTGATGC Ven-R2  
30 GACTGCAGAGATTCCTCTC Nan5HA-R  
31 GCTATATCCCCTAATTTGTTGG Nan3HA-F  
32 GTCGATGCGACGCAATCGTC Hyg-F  
33 CAAGCTGAAGGTGACCAAG mCh-F Genotyping pOC 
34 CGATACCGTAAAGCACGAG Neo-R2  
35 GGACTATCATATGCTTACCGTAACTT hU6Prom-F Seq gRNA 
36 CGATCAAGCAGCGACTATGC Oct-F OCT4 PCR 
37 CTATCTACTGTGTCCCAGGC Oct-R  
38 CCTGGTGGCCAAGACAGAAGAGATG OctUps5´HA-F  
39 GGGAGAAGATGCTTTGAGCTCCCTC OctDst3´HA-R  
40 AGTGCCAGGGCTGCTTAAGAAATTG NanUps5´HA-F NANOG PCR 
41 CGAAGAATAGCAATGGTGTGACGCA Nan-F1  
42 CAGGCACAAGATGGGAAAAGGACAG NanDst3´HA1-R  
43 CATCATGCTGCTTCAGAGTGAAGGG NanDst3´HA1-R  
44 GCAGTTCCAGCCAAATTCTC Nan-F2  
45 ACACCTGATCAAGCCTGTTCATTTGATTAC SurvCtrl-F Surveyor assay ctrl. 
46 CGCCAAAGAATGATCTGCGGAGCTT SurvCtrl-R  
47 GATGGAGAGTCTCGCCTCATTGTCA OctP5-F CRISPR off-target 
48 GCCAGTCCTATCTCTCTCCTCTCCT OctP5-R  
49 GTCCACACTTAAGGACTGGGGAGTT OctP3-F  
Methods 
36 
 
50 AGCTCCTGAAGCAGAAGAGGATCAC OctP3-R  
51 GACATGCAAAGCAGAAACCCTCTTG OctP4-F  
52 AATTTCAGGAGCAATACACGCTGGT OctP4-R  
53 CATTTGTCACAGTGGATGACCCCAC OctP6-F  
54 GAACATGTGTAAGCTGCCTCCCTTG OctP6-R  
55 GGAATTTCTTTGGTTGCAGCCCATT Oct1b-F  
56 AGAAACTGAGGCTTAGGAAGGGAGT Oct1b-R  
57 CTATGGTTTGTGCGCTCCTTATTGC NanP8-F  
58 CTTGCCTTGCTTTGAAGAATCCGAC NanP8-R  
59 AAGGCACAGAAACAACCAAGCTCAG NanP7-F  
60 CCTACCCCAGCCTCTACTCTTCCTA NanP7-R  
61 TCACCTCAATCCTTCACCCTTCACC NanP9-F  
62 TGTTTTGCTAGACTGAGCTGGTTGC NanP9-R  
63 GGTATGTGTCAGCACACTCCCTCTT NanP1a-F  
64 ACAACCAGAACTGTCTGTGACTGGA NanP1a-R  
65 ACACACAACTCCAGTCACAGACAGT NanP1b-F  
66 TTCTGCCCTAGGTCTTCACCTCAAC NanP1b-R  
67 ACTTTTCTCACTGGCTTTCCCATGC NanP2-F  
68 CCACTGTTTGGTCCAATTGCCTCAT NanP2-R  
69 TCGAGGAGAAGATGTTGAGTTGGTT NanP10-F  
70 GAGCTGGTTGCCTCCTGTTATTGTG NanP10-R  
71 TCCATCCTTGCAAATGTCTTCTGCT NanP4-F  
72 GGCTTCTTTTCTGTCTAAGGGCTGT NanP4-R  
73 TGGGAGGCTTCTTCTACTTTCTGGA NanP5-F  
74 GCAGCTGCAAGAACTTTCCAATACC NanP5-R  
75 TAACATGAGTGTGCATCCAGCTTGT NanP6-F  
76 TAGTAAAACACAGAGCCAAAGGGGC NanP6-R  
2.3. Cloning 
2.3.1. Sequencing, subcloning and transformation into competent cells 
For sequencing genomic DNA the stretch of DNA to be sequenced was amplified by PCR, while plasmid DNA 
was directly send to GATC LIGHTrun for sequencing. 
The PCR product was extracted from the gel with either the ZymocleanTM Gel DNA Recovery Kit (Zymo 
Research), MinElute Gel Extraction Kit or QIAquick Gel Extraction Kit (both Qiagen) following 
manufacturers´ protocol. The PCR product was eluted in water and sequencing was either performed on the 
PCR product or on the Miniprep obtained after an additional subcloning step allowing for clonal analysis of 
the DNA. DNA concentration was determined on a NanoDrop2000 Spectrophotometer (Thermo Scientific). 
Subcloning was performed with the Zero Blunt TOPO PCR Cloning Kit using One Shot(R) Competent E.Coli 
(both Life Technologies) following manufacturer´s protocol. In brief, 20 ng of gel-purified PCR product was 
used in a maximal volume of 4µl. The TOPO cloning vector was incubated with the PCR product for 30 
minutes at room temperature. The ligated TOPO cloning vector was transferred to One Shot(R) Competent 
E.Coli and after 5 minutes incubation on ice heat shocked for 30 seconds at 42°C. 250 µl SOC medium was 
added to the transformed bacteria. After 1 hour incubation at 37°C 100 µl or 150 µl of the transformed cell 
solution (300 µl total volume) was streaked out on the LB-kan plates which were grown at 37°C for 14-16 
hours. Colonies were grown in 5 ml LB with 50 µg/ml kanamycin 14-16 hours at 37°C. Plasmid DNA was 
extracted from 2 ml of the overnight culture with the QIAprep Spin Miniprep Kit (Qiagen). The TOPO cloning 
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vector contains EcORI restriction sites on either side of the insertion site. Restriction digestion with Fastest 
Digest EcORI (Thermo Scientific) was performed to test for the uptake of the PCR product in the subcloning 
vector.  
2.3.2. Reporter plasmid construction by Seamless cloning 
A NV and an OC reporter plasmid were produced (Figure 6). For both pOC and pNV four DNA fragments 
were assembled with GeneArt(R) Seamless Cloning Enyzme Mix (Life Technologies) in one step. Seamless 
cloning was based on an 18 bp complementarity of the ends of the DNA fragments. 
The DNA fragments (vector backbone, the 5´ HA, the 3´HA and reporter constructs) were obtained by PCR 
or ordered as custom-made synthesized DNA blocks (gblocks from IDT; sequences are shown in the 
appendix). The complementarities of the DNA fragments were attained by primer tails (shown in Table 1) 
and adding complementary sequences to each end of the DNA blocks (shown in appendix). 
The vector backbone was amplified from pBR322 (New England Biolabs). The reporter constructs were 
amplified from VENUS-Hygromycin and mCHERRY-Neomycin reporter vectors that were a generous gift of 
Josh Brickman´s lab. Both the VENUS-Hygromycin and mCHERRY-Neomycin constructs start with a stretch of 
18 bp encoding a Glycine-Serine linker, and the fluorescence and antibiotic resistance gene are connected 
via a T2A-encoding sequence (see Figure 6). The Glycine-Serine linker was prolonged with 12 bp by primer 
tails (Table 1) or incorporation of the corresponding bp sequence in the DNA block (Appendix). The OC-5´HA 
and the NV-3´HA were amplified from genomic DNA of HuES4 cells, while OC-3´HA and NV-5´HA were 
ordered as DNA blocks. The sequences of the gel-purified PCR products were validated by sequencing. All 
HAs are 720 bp, except the 884 bp NV-3´HA. 
Seamless cloning was performed according to manufacturer´s protocol. In brief, 30 ng of the HAs, 60 ng of 
the reporter constructs and 100 ng of the vector backbone were mixed in a total volume of 5 µl. 5 µl 
Seamless enzyme mix was added and incubated 30 minutes at RT, followed by 5 minutes incubation at 4°C. 
The procedure for transforming plasmids to competent bacteria is described in paragraph 2.3. However, to 
increase the number of colonies the complete 10 µl volume of the ligated reporter plasmids was used for 
transforming One Shot(R) Competent E.Coli and all bacteria were spread on the LB plate by spinning down 
and resuspending in a smaller volume.  
The correct assembly of the reporter vector was determined by restriction analysis as described in section 
2.3. pOC was either digested with Stu-1 or EcORI and pNV with EcORI and EcORV (Fastest Digest Thermo 
Scientific). The restriction sites are marked in Figure 6. Maxipreps were prepared with the Plasmid Filter 
Purification Kit (JetStar) following manufacturer´s protocol. In brief, the bacteria were grown in 250 ml LB 
medium with 100 µg/ml carbenicillin overnight, and the cells were centrifuged at 6000 g for 15 minutes at 
4°C. After purification the plasmid DNA was resuspended in 100 µl water. The sequence of the reporter 
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construct and the HAs were validated by sequencing. Bacterial glycerol stocks from sequence-validated pOC 
and pNV are stored at -80°C.   
 
Figure 6: pOC and pNV reporter plasmids with used restriction sites. Abbreviations: rep constr – reporter construct; AmpR – 
Ampicillin resistance; Ori – origin of replication; bb - backbone 
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2.3.3. CRISPR plasmid cloning 
The CRISPR plasmids pX330 and pX335 were obtained from Addgene (Feng Zhang Lab). The CRISPR guide 
sequences were designed based on the online CRISPR design tool from Zhang´s lab [251]. Details on the 
guide sequences are listed in Table 2. In general all guide sequences close to the intended insertion sites at 
the stop codons of OCT4 or NANOG have a low quality score due to the high degree of sequence similarity 
of the many OCT4 and NANOG pseudogenes. 
The CRISPR guide sequences were cloned into the CRISPR vectors pX330 and pX335 (Addgene; plasmids   
42230 and 42335) following a previously published protocol [19]. In brief, two DNA oligos were generated 
containing the 20 bp guide sequence, and CACC(G) was added 5´ to the forward sequence while AAAC and 
(C) was added to the reverse complement (Table 2). The G and C in parenthesis were only added, if the 
guide sequence begins with a nucleotide other than a G. The CRISPR plasmids were digested with BbsI 
(Thermo Scientific) and gel purified with the QIAquick Gel Extraction Kit (Qiagen). The oligos were 
phosphorylated and annealed with a T4 Polynucleotide kinase (New England Biolabs) in a thermocycler with 
a ramp down protocol (Table 3).  
One Shot(R) Competent E.Coli were transformed with the ligated CRISPR vector as described in paragraph 
2.3.1. The CRISPR vector was sequenced to confirm the correct insertion of the guide sequence. Maxipreps 
were prepared as described in 2.4.1. 
Table 2: Oligo sequences for cloning CRISPR vectors and specifics of CRISPRs. Bold sequence is the guide sequence; Quality score 
(0-100) was obtained from online CRISPR design tool from Zhang´s lab and a low score implies an increased chance of off-targets; 
Distance refers to the distance of the expected cut site to the insertion site of the reporter construct, where * marks the cut sites 
that are within the coding region; Dn off-set refers to the distance between the guide sequences of the double nickase pair. 
 
  
Sequence (5´-3´) Target Guide Quality 
score 
PX300 or 
PX335 
Distance 
(bp) 
Dn off-set 
(bp) 
CACCGAACTTAATCCCAAAAACCC OCT4 1 42 N 60  
AAACGGGTTTTTGGGATTAAGTTC       
CACCGGAGCTAGGGAAAGAAAACC  2 28 DnA 80 63 
AAACGGTTTTCTTTCCCTAGCTCC       
CACCGCCAGAGTGGTGACGGAGACA  3 22 DnB 37 * 63 
AAACTGTCTCCGTCACCACTCTGGC       
CACCGCTCAATTTCAGTCTGGACAC NANOG 1 17 N1 & DnA 41 13 
AAACGTGTCCAGACTGAAATTGAGC       
CACCGTGTTTGGAAACCACGTGTTC  2 33 N2 110  
AAACGAACACGTGGTTTCCAAACAC       
CACCGACTCATCTTCACACGTCTTC  3 18 DnB 6 * 13 
AAACGAAGACGTGTGAAGATGAGTC       
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Table 3: Thermocycling programs 
Ramp down to anneal CRISPR plasmids cDNA synthesis 
1 37°C 30 min  1 25°C 5 min 
2 95°C 5 min  2 50°C 45 min 
3 95°C 15 sec -2°C/cycle 3 55°C 10 min 
4 GoTo 3 36x  4 70°C 15 min 
5 12°C ∞  SYBR qPCR 
Surveyor reannealing 1 50°C 2 min 
1 95°C 10 min  2 95°C 2 min 
2 95°C 1 sec -2°C/cycle 3 95°C 15 sec 
3 GoTo 2 5x  4 60°C 25 sec 
4 85°C 1 min -10°C/cycle 5 73°C 30 sec 
5 GoTo 4 8x  6 GoTo 3 45 x 
6 4°C ∞  7 95°C 15 sec 
    8 70°C 15 sec 
    9 98°C 15 sec 
2.5. Transfections 
2.5.1. Nucleofection of human embryonic stem cells 
hESC were transfected using a Amaxa 2b Nucleofector Device (Lonza). Transfections were performed with 
the Human Stem Cell Nucleofector Kit 2 (Lonza).  
To increase the efficiency of homologous recombination the reporter plasmids were linearized, pNV and 
pOC were digested overnight with the high fidelity enzymes HindIII-HF and PVUI-HF (both New England 
Biolabs), respectively.  
Digested DNA was ethanol-precipitated. 10 % of the volume 3M sodium acetate was added to the 
restriction digestion, followed by 2 volumes ice cold ethanol. The DNA was precipitated by mixing, 15 
seconds incubation in dry ice and centrifuging at 20000 g for 15 minutes at 4°C. The pellet was washed in 70 
% ice cold ethanol twice and resuspended in H2O to obtain a concentration of 1-2 µg/µl DNA. Around 250 
ng DNA was run on a 0.8 % agarose gel to confirm the length of digested vector. 
Two million HuES4 hESCs (passage ≤35) were used for each transfection, and the transfected cells were 
transferred to 2 wells of a 6-well plate seeded with DR4MEFs and conditioned with hESC medium with 10 
µM ROCK inhibitor 6 hours prior to transfection. In all transfections 10 µg DNA in a maximal volume of 10µl 
H20 or TE buffer was mixed with 100 µl transfection buffer. An optimization was performed to find the best 
transfection program. Two µg of pMaxGFP was co-transfected with 8 µg pEFBOS-Cre IRESpuro. In all 
following transfections program B-016 was used, which gave a transfection efficiency of over 50 % (data not 
shown). In total 5 µg of reporter vector(s) and in total 5µg of CRISPR vector(s) or 10µl H20 as a negative 
control were mixed with the transfection buffer and kept at RT. The harvested cells were centrifuged, 
resuspended in the transfection buffer with or without DNA, and transfected. 500 µl hESC media with 10 
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µM ROCK inhibitor was added to the cuvettes and the cells were transferred to the conditioned 6-well 
plates. Positive selection was started 2-3 days post transfection before the cells get confluent. 
2.5.2. Transfection of HEK293 cells 
Lipofectamine 2000 (Life technologies) was used for the co-transfection of HEK293 cells with CRISPR 
plasmids and the GFP-expressing pMaxGFP. 1 well of a 70-90% confluent 6-well plate was transfected with 
1µg of each of 1 or 2 CRISPR vectors and 200 ng of pMaxGFP using 9 µl Lipofectamine 2000 according to 
manufacturer´s protocol. The wells were washed 5-16 hours post transfection, and the cells harvested for 
FACS 1 or 2 days post transfection. 
2.6. Flourescence-activated cell sorting 
A FACS Aria III (BD) was used for FACS. The machine is operated with the BD FACSDiva software. HEK293 
were harvested as described above and resuspended in 0.5 to 1 ml PBS-/- containing 0.1 % DAPI and 0.5-2.5 
% BSA (Sigma), transferred to polystyrene round bottom FACS tubes (BD) through a Cell Trics 100 µm cell 
strainer (Partec), and placed on ice. The cells were gated for size (SSC-A/FSC-A & FSC-H/FSC-W) and viability 
(DAPI/FSC-A). Fluorescent cells were determined by comparison with non-transfected HEK293 cells.  
2.7. Immunofluorescence 
Pluripotent or differentiated hESC were washed with PBS and fixed 20-30 minutes in 4% paraformaldyde. 
After 3 washes with PBS lasting 5 minutes each, the cells were permeabilized with PBS containing 0.5% 
Triton X-100 (PBS-0.5%TX-100) for 15 minutes. Blocking was performed in blocking buffer, PBS-0.1%TX-100-
5% Normal Donkey Serum (Jackson), for 1 hour at RT. Primary antibodies were applied in blocking buffer at 
4°C ON. All antibodies are listed in Table 4. 3 washes with PBS-0.1%TX-100 were performed and the cells 
were incubated with the appropriate secondary antibody for 1 hour at RT. Cells were washed 3 times, the 
first with PBS-0.1%TX-100, the second with PBS-0.1% DAPI and the third with PBS. The cells were stored in 
PBS at 4°C until analysis. 
Fluorescence microscopy was performed with a Nikon Eclipse Ti microscope with 4x, 10x or 20x objectives 
or with a Leica AF600 microscope with a 20x objective using ImageJ and Leica Application Suite software, 
respectively. 
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Table 4: Primary and secondary antibodies. Abbriviations: conc – concentration; Cat. num. – catalogue number; gt – goat; mm – 
mouse; rb – rabbit; dk – donkey; HRP – horseradish peroxidase 
1. Antibody Conc. Company  Cat. num. 2. Antibody Conc. Company  Order number 
Gt-α-SOX17 1:1000 R&D AF1924 488 dk-α-gt 1:500 Life Techn A11055 
Gt-α-Hnf3ß 1:200 Santa Cruz Sc-6554 488 dk-α-mm 1:500 Jackson 715-545-150 
Mm-α-NANOG    1:400 BD 560482 488 dk-α-rb 1:500 Jackson 711-545-152 
Mm-α-OCT4 1:500 Santa Cruz Sc-5279 546 dk-α-gt 1:500 Life Techn A11056 
Gt-α-OCT4 1:500 Santa Cruz Sc-8628 592 dk-α-mm 1:500 Life Techn A21203 
Rb-α-OCT4 1:500 Abcam Ab19857 CY3 dk-α-rb 1:500 Jackson 711-165-152 
Gt-α-GFP 1:1000 Abcam Ab5450 555 dk-α-Rb 1:500 Life Techn A31572 
Rb-α-GFP 1:1000 Abcam Ab6556 647 dk-α-mm 1:500 Life Techn A-31571 
Rb-α-RFP 1:500 Abcam Ab34771 CY5 dk-α-gt 1:500 Jackson 705-175-147 
Gt-α-Hand1 1:500 R&D AF3168 647 dk-α-rb 1:500 Life Techn A31573 
    HRP gt-α-mm 1:5000 Santa Cruz Sc-2005 
    HRP α-rb 1:5000 Jackson  
    HRP α-gt 1:5000 Jackson  
2.8. Western blotting 
Cells were harvested and the pellet stored at -20°C until protein extraction. The pellet was resuspended and 
incubated 5 minutes in lysis solution, containing 50 mM Hepes pH 7.6, 150 mM NaCl, 5 mM EDTA, 10 % 
glycerol, 0.5 % TX-100, protease inhibitors (Roche) and phosphatase inhibitors (Sigma). 
Protein concentration was measured with Pierce BCA Protein Assay Kit (Thermo Scientific) according to 
manufacturer´s protocol. Lysates were loaded into 4-12 % Bis-Tris Sodium dodecyl sulfate (SDS) 
polyacrylamide gels in 1 times MOPS SDS Running Buffer. The gels were transferred to nitrocellulose 
membranes. The nitrocellulose membrane was stained with Ponceau dye to confirm the presence of 
protein in the samples.  
The membranes were blocked for 1 hour in PBS with 0.5 % Tween20 (PBST) and 5 % milk, and incubated 
with the primary antibody in blocking buffer ON. Antibodies are listed in table 4. Subsequent to 3 washes in 
PBST, the blot was incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at RT. 
After 3 washes in PBST Amersham ECL Prime Western Blot Detection Reagent (GE Healthcare) was applied 
for 1 minute and the membrane was imaged with a Chemi Doc MP Imager (Bio-Rad) and edited with Image 
Lab software. 
Before reblotting ECL was washed off with PBST and antibodies were removed with Restore PLUS Western 
Blot Stripping Buffer (Thermo Scientific). 
2.9. Surveyor assay 
The Surveyor Mutation Detection Kit (Transgenomics) was applied following a published protocol [257] to 
test for mutations at CRISPR on- and off-targets. The sensitivity of the Surveyor assay was tested by mixing 
the in the Surveyor kit included DNA sequences in different concentrations. 
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Only off-target sites with high probability of off-target activity were analyzed. Additionally, comparatively 
weak off-targets within NANOG or OCT4 pseudogenes were analyzed, since a double-strand break at the 
pseudogene locus potentially induces integration of the reporter construct to the high degree of sequence 
similarity to the HAs. 
Primers for amplification of the genomic DNA sequences containing the on- or off-target sites were 
designed  in order to yield PCR products 2-4 kb in length with the expected CRISPR recognition sequence at 
least 500 bp away from the edge and not exactly in the middle. The primers are listed in Table 1. 
10 % of the PCR products was applied to an agarose gel to confirm a single PCR product of the correct size 
and the remaining PCR product was purified with the MinElute Gel Extraction Kit (without running them on 
an agarose gel). DNA reannealing was achieved by heating the DNA to 95°C and then from 85°C slowly 
decreasing the temperature with 0.3°C/second (Table 3). The on-target PCR products obtained from NV and 
OC hESC reporter lines were mixed 50:50 with PCR products from wt HuES4 genomic DNA. The reannealed 
PCR products were digested 1 hour with the Surveyor nuclease at 42°C, and the digested DNA was run on 
an agarose gel. 
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3. Results 
Fluorescent reporter lines have proven to be an invaluable tool in PSC research [8, 10]. The easiest way to 
produce reporter lines is by random integration of the promoter from the gene of interest upstream to the 
reporter gene. However, the transgene might be subject to position effects and faithful report of the gene 
of interest cannot be warranted [208, 306]. To obliterate position effects in the production of reporter lines 
gene targeting has been successfully applied [8, 220, 307]. Gene targeting depends on the rare events of 
spontaneous homologous recombination and although feasible more efficient methods for reporter line 
productions would be clearly beneficial.  
The recently developed CRISPR-Cas9 system from S. pyogenes has proven to facilitate gene targeting, e.g. 
efficient generation of fluorescent reporter mice [21] and homologous recombination using short donor 
templates in human cells have been achieved [15]. However, there is limited knowledge on gene targeting 
using long donor templates in PSCs [22]. To test the feasibility of using the CRISPR-Cas9 system in the 
production of hESC reporter cell lines, a NV and an OC reporter line were produced and characterized.  
3.1. Cloning NANOG-VENUS and OCT4-mCHERRY reporter plasmids 
3.1.1. Reporter constructs are designed to grant a faithful reporter, rapid 
customizable cloning and high relative targeting efficiencies 
Several aspects were considered in the design of the reporter constructs. The primary focus in the design 
was to create faithful reporters that could be rapidly derived.  
Targeting pluripotency factors were expected to simplify the production and characterization of 
reporter lines in hPSCs, since they are expressed in hPSCs. The production is thought to be facilitated by the 
possibility to use a promoter trap approach that requires expression of the targeted allele in the cells. The 
promoter trap strategy is further discussed later in this paragraph. Furthermore characterization of a 
reporter line requires expression from the promoter of interest; by choosing pluripotency transcription 
factors the cells do not need to be differentiated for basic characterization of the reporter line. 
To increase the generality of the findings, two pluripotency factors were targeted. Additionally, creating two 
reporter constructs would allow testing, whether the CRISPR-Cas9 system could increase the homologous 
recombination efficiency sufficiently to target two endogenous genes simultaneously. The core pluripotency 
transcription factors NANOG and OCT4 were chosen as targets. hPSC reporter lines for NANOG and OCT4 
have been produced before [17, 220, 300], which proofs the feasibility of targeting NANOG and OCT4 in 
hESCs. Hence, complications with the targeting procedure will likely not arise due to complications with 
targeting the specific loci. 
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 Another important aspect of the reporter design is whether to express only the transgene or both 
the endogenous gene and the transgene from the targeted allele. Here the genes encoding the fluorescent 
proteins mCHERRY and VENUS were chosen for targeting the 5´ side of the stop codons of OCT4 and 
NANOG, respectively (Figure 7). Thereby OC and NV fusion proteins would be created. The feasibility of 
fusing OCT4, NANOG, mCHERRY and VENUS to other proteins in reporter lines has been previously shown 
[17, 204, 300, 308].  
A key property of reporter lines is that they report the dynamics of an endogenous protein. However, 
fluorescent proteins have long half-lives and they may be expressed long after the endogenous protein is 
lost [309]. This obviously does not allow a faithful report of the dynamics of the protein. The effect of fusing 
the proteins on the stability is not well understood. However, there are some indications that fusion 
proteins acquire the stability of the endogenous protein. It was for instance observed that NANOG had a 
very similar half-life as a NV fusion protein [296].  
To allow proper folding of the fused proteins, a linker encoding glycine (G) and serine (S) residues 
(GGSGGSGSGS) needs to be inserted between OCT4 and mCHERRY, as well as NANOG and VENUS. The GS-
motif is among the most common motifs used in flexible linkers [310]. The small size of glycine allows 
flexibility and the polarity of serine solubility in aqueous environments. A flexible linker was chosen since it 
allows independent movement of the fused proteins and thereby decreases the chance of steric hindrance 
of the reporter protein for the function of the endogenous protein. 
Homologous recombination depends on HA. Previoulsy, HAs with at least 1.6 kb and up to 
120 kb have been used [208, 213]. Enlarging the HA(s) is thought to increase the homologous 
recombination efficiency, likely due to providing a larger stretch of homologous DNA for the seeding of the 
homologous recombination process [12]. Additionally, it increases correct targeting to the intended locus 
due to the longer stretch of sequence homology between target and donor DNA. However, the retrieval of 
long HAs from BACs is a tedious process involving several cloning steps [213]. Therefore, it was chosen to 
use short HAs in the reporter plasmid that can rapidly be generated by PCR-amplifying genomic DNA or 
even by generating sequence-validated synthesized DNA blocks. At the moment DNA blocks can be 
obtained with a maximal length of 750 bp. Since the CRISPR-Cas9 technology greatly increases the 
efficiency of homologous recombination [14, 15, 19, 21, 22], it can be expected that homologous 
recombination would still occur with short HAs. In the DNA blocks point mutations can be integrated that 
mutate the PAM sequences of the applied CRISPRs. By mutating the PAM sequence the ability of the 
CRISPRs to induce double-strand breaks is disrupted [236, 241]. Hence, the potential for double-strand 
breaks and subsequent indels in the reporter vector and the homologously recombined allele is removed. 
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Figure 7: Gene targeting scheme. NV (A) and OC (B) reporter lines were produced by gene targeting. The procedure depends on 
HA in the reporter vectors (pOC, pNV) that are homologous to the target sequence (indicated by crossed lines). CRISPR-induced 
double-strand breaks (DSBs) attract the DNA repair machinery and thereby facilitate homologous recombination through HDR. 
The reporter cassettes are inserted prior to the stop codon and both the fluorescence (VENUS, mCHERRY) and antibiotic 
resistance (Hygromycin, Neomycin) genes are transcribed with NANOG or OCT4 using the endogenous promoter and 
endogenous 3´UTR. While the fluorescent proteins are fused to the pluripotency transcription factors via a flexible linker (GS 
linker), the antibiotic resistance proteins are cleaved off during translation due to the T2A self-cleaving peptide. 
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As previously mentioned, positive selection of correctly targeted clones may be based on driving the 
expression of an antibiotic resistance gene from an exogenous promoter or from an endogenous promoter. 
Since NANOG and OCT4 are transcribed in hPSCs the promoter trap strategy can be employed with the 
advantage of saving the time associated with excision of the exogenous promoter after positive selection 
[17, 208]. Furthermore the promoter trap is expected to increase the relative targeting efficiency, since the 
selection marker is only expressed, when the transgene is inserted into the reading frame of an expressed 
gene.  
The promoter trap requires multicistronic expression from the endogenous promoter. The IRES sequence is 
widely used to allow the derivation of two proteins from one transcript. However, differences in expression 
levels between the genes upstream and downstream of IRES [311], decreased stability of the endogenous 
mRNA [301], and poor performance in hESCs have been reported [214]. Due to its small size and high 
cleavage efficiency family of 2A peptides seem to be the better alternative for bicistronic transgene 
expression (Kim et al., 2011; [214]. Therefore, a sequence encoding a 2A self-cleaving peptide was inserted 
between the fluorescent and antibiotic resistance genes. 2A peptides cleave themselves at the C-terminus, 
leaving a tag on the upstream protein [312]. The T2A peptide was chosen since it is the smallest of 2A 
peptides and leaves a shorter tag on the upstream protein.  
3.1.2. Seamless cloning allow efficient cloning of reporter constructs 
Molecular cloning traditionally depended on the existence of restriction sites and the action of restriction 
endonucleases that leave behind scars in the recombinant DNA sequence [313, 314]. When several DNA 
segments were assembled, it was usually accomplished in consecutive cloning steps. Recently alternative 
cloning strategies have emerged that promise the possibility of directional ligation of multiple fragments. 
Here GeneArt® Seamless cloning was applied to assemble four DNA fragments to either the NV or OC 
reporter plasmid (pNV, pOC) in one cloning step (Figure 8). For both pNV and pOC the DNA fragments were 
the vector backbone, 5´ HA, reporter construct and 3´HA.  
The HAs used for pNV and pOC are 720 or 889 bp (Figure 7). Not all HAs could be obtained as synthesized 
DNA blocks due the occurrence of motifs such as multiple TTT´s in the DNA sequences that according to the 
manufacturer complicates the synthesis. The 5´HA of pOC and the 3´HA of pNV were instead amplified from 
genomic DNA. The vector backbone and the reporter constructs were also PCR amplified. Both the VENUS-
HYGROMYCIN and the mCHERRY-NEOMYCIN constructs are composed in the same way; a flexible linker 
precedes the fluorescence gene that is connected to the antibiotic resistance gene via T2A (Figure 6, Figure 
7, Figure 8). 
Seamless cloning of the pNV and pOC fragments yielded 20 and 14 colonies, respectively. Restriction 
digestion confirmed at least eight and five correctly assembled clones, respectively (Figure 9). One pOC  
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Figure 8: Reporter plasmid cloning scheme. OC (A) and NV (B) reporter plasmids were produced by assembling 4 DNA fragments 
by Seamless cloning. The DNA fragments were either amplified by PCR or synthesized DNA blocks (marked with an asterisk). 
Ligation of the fragments depends on overhangs on each end of the fragments that are homologous to the adjacent fragment. 
The combined lengths of the overhangs of adjacent fragments are 18 bp (C).  
 
Figure 9: Seamless cloning efficiently 
assembles 4 DNA sequences to reporter 
plasmids. 20 and 14 bacterial colonies 
were growing after cloning pNV and pOC 
with GeneArt® Seamless cloning. The 
extracted plasmids were analyzed by 
restriction digestion (A, B). To confirm the 
5 pOC clones with the expected band 
profile in the EcORI digestion, they were 
additionally digested with StuI. Expected 
band lengths are shown in a table (C). 1 kb 
plus DNA Ladder (Invitrogen) was used. 
Bands under 300 bp were not clearly 
visible on the gels. 
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clone and one pNV clone were confirmed by sequencing (data not shown). Seamless cloning proved to be a 
time-saving cloning strategy that enabled simultaneous and directional ligation of four DNA fragments 
without leaving restriction scars. 
3.2. CRIPSR plasmids are rapidly produced and tested 
3.2.1. CRISPRs targeting the stop codon of NANOG or OCT4 likely have off-
target effects in NANOG and OCT4 pseudogenes 
To increase the number of the homologous recombination events the CRISPR-Cas9 technology is employed. 
By inducing double-strand breaks close to the on-target site the CRISPRs attract the DNA repair machinery 
and thereby facilitate homologous recombination through HDR.  
Here both the double nickase and the nuclease strategies for inducing double-strand breaks are employed, 
since each of the strategies has its advantages. Nucleases were found to more robustly facilitate 
homologous recombination, and double nickases likely give less off-target effects [14].  
To identify the best guide sequences, regions of 250 bp upstream and downstream of the insertion sites of 
the reporter constructs prior to the stop codons were analyzed for potential CRISPR guide sequences with 
the online CRISPR Design Tool (Feng Zhang´s lab).  
Several considerations were taken into account in the choice of guide sequences. The guide sequences 
should be as close as possible to the insertion site to allow efficient recombination [14], and have the least 
possible homology to other sequences in the genome to reduce the chance of off-target effects [250, 251]. 
Additionally the CRISPRs should cut outside of the coding sequence and important regulatory sequences, 
such as the polyadenylation signal, to reduce the impact on the non-targeted allele. The non-targeted allele 
is likely affected by the CRISPR, since the efficiency of inducing indels is considerably higher than the 
efficiency of inducing HDR [14, 20, 21]. Finally, the nickase pairs should produce 5´overhangs upon double-
nicking and to be off-set optimally with 0-20 bp, since this experimentally was determined to be optimal for 
reducing off-target effects and ensuring on-target effects [14]. 
Based on these guidelines two nucleases and one double nickase targeting NANOG (NAN-N1, NAN-N2, 
NAN-Dn) as well as one nuclease and one double nickase targeting OCT4 (OCT-N, OCT-Dn) were designed. 
The reason for choosing two nucleases for NANOG was that NAN-N2 is less likely to have off-target effects 
and NAN-N1 is closer to the stop codon. Guide sequence characteristics like the quality score, distance to 
the insertion site and the distance between the two nickase pairs are listed in table 2. Figure 10 additionally 
shows the location of the target sequences in regard to the NANOG and OCT4 coding sequences, and in 
table 5  potential off-targets are listed.  
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Figure 10: Guide sequences of the used CRISPRs. The guide sequence for NAN-N1 is the same as for NAN-DnA. The coding 
sequences are marked in yellow and the PAM sequences in purple. 
The quality scores of the guide sequences are low in comparison to other loci, and the main reason is that 
both NANOG and OCT4 have several related pseudogenes (NANOGP1-11, OCT4P2-8). Additionally, OCT4 has 
an intronless homologue called OCT4-1b (previously OCT4P1) that produces a functional protein with 95 % 
sequence homology to OCT4 [315]. Many of the pseudogenes are highly homologous to OCT4 and NANOG, 
which complicates finding target sequences that are unique in the human genome. Even the best guide 
sequences found in proximity of the NANOG and OCT4 stop codons are still not unique or have only 1 or a 
few mismatches with other sequences in the genome. Further complications might arise from the 
circumstance that NANOGP1 is directly downstream of NANOG. Two CRISPR-induced double-strand breaks 
in close proximity to each other can facilitate a genomic deletion of the sequence between the two cuts 
[14]. Such deletions might occur in some cells transfected with CRISPRs targeting NANOG with the 
consequence of reducing the number of correctly targeted NV clones. Therefore, possible secondary effects 
of targeting the pseudogenes need to be considered when analyzing the positive clones for activity of the 
fusion proteins. 
3.2.2. CRISPRs targeting OCT4 induce mutations only at on-target sites in 
HEK293 cells 
A great advantage of the CRISPR technology over related genetic engineering tools such as zinc fingers and 
TALENS is the ease of its assembly. The specificity of the CRISPR is conferred only by a 20 bp guide 
sequence, and a time-saving protocol for inserting the guide sequence to the gRNA in one cloning step has 
been developed [19]. The CRISPR plasmids pX330 and pX335 express a gRNA and human codon-optimized 
S. pyogenes Cas9 or Cas9n, respectively (Figure 11). Cas9 or Cas9n is expressed from the recently developed 
hybrid CBA (CBh) promoter that is a hybrid of the commonly used cytomegalovirus (CMV) and chicken-beta-
actin (CBA) promoters, optimized for expression in various human cell types [316]. gRNA expression is 
driven by the human U6 promoter that allows ubiquitous transcription by the small RNA-expressing RNA 
polymerase III [317]. The correct insertion of the guide sequences in all CRISPR vectors were confirmed by 
Sanger sequencing (data not shown). 
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Figure 11: Schematic of CRISPR plasmids. 
The CRISPR plasmids pX330 and pX335 
express a guide RNA (gRNA) from the 
human U6 promoter and a human 
codon-optimized S pyogenes (hSP) Cas9 
or Cas9n from the CBh promoter. The 
humanized Cas9 gene contains nuclear 
localization signal (NLS) domains. 
Modified from [19]. 
                                
To assess whether the designed CRISPRs are capable of inducing double-strand breaks and consequently 
can be expected to facilitate homologous recombination, a pilot experiment was performed in HEK293 cells. 
HEK293 cells are more easily cultured and transfected than hESCs and suffice as a system to compare the 
activity of different CRISPRs. Additionally it is assessed whether the designed CRISPRs induce mutations at 
off-target loci in the HEK293 cells. Excessive off-target activity could in addition to disrupting the function of 
the targeted sequence also lead to genomic instability [253, 254]. In consideration of the poor quality of the 
CRISPR targets, it is relevant to test whether several off-targets are affected, and genomic instability may 
become a problem in prospective reporter lines. 
HEK293 cells were cotransfected with GFP-expressing pMaxGFP and either one nuclease 
vector or two nickase vectors. Based on the assumption that GFP+ HEK293 cells also have taken up the 
CRISPR plasmid(s), at least 105 GFP+ cells were isolated by FACS and immediately harvested for DNA 
isolation. On-target DNA sequences were amplified by PCR, and the PCR-product was sub-cloned and 
assessed for mutations by Sanger sequencing. Four bacterial clones were analyzed for each CRISPR, and 
while 75 % of OCT-Dn and OCT-N clones showed mutations in proximity to the expected sites, only 25 % of 
NAN-N1, 0 % NAN-N2 and 0% NAN-Dn clones had mutations at the expected sites (Figure 12). The most 
common mutations were deletions. 
On- and off-target DNA sequences were amplified by PCR, and Surveyor analysis was performed on a 
population basis for both on- and off-targets. The assay is based on the Surveyor T7 endonuclease that 
detects nicks in a DNA sequence and induces a double-strand break at the nick [257]. If there are indels due 
to CRISPR-mediated NHEJ, a reannealing step prior to Surveyor digestion facilitates a random hybridization 
of differently mutated or mutated and non-mutated DNA strands. The advantages of the Surveyor assay 
over Sanger sequencing is the possibility to rapidly screen populations of cells for mutations at several 
genomic loci in a cost-effective manner.  
In a control assay the sensitivity of the surveyor analysis was tested, and it was shown that a point mutation 
could be detected, when only 3 % of the DNA contained the mutation (Figure 13). Hence, the surveyor 
assay can detect mutations with high sensitivity. 
The Surveyor analysis of OCT4-CRISPR confirms the efficient cleavage at the on-target site for both the 
nucleases and double nickases (Figure 13). When either one of the nickases were transfected alone no 
Results 
52 
 
mutations were detected. This confirms previous studies that have found single nickases to be inefficient 
inducers of mutations [14, 15, 252, 255]. At off-target sites no indels are detected. In the analysis of 
NANOG-CRISPR indels were neither detected for on-target nor off-target sites in the Surveyor analysis. 
Based on the Sanger sequencing of the on-targtet sites this result was at least partly unexpected. Since 
NAN-N1 was found to induce mutations in the Sanger sequencing, it was expected to be reflected in the 
Surveyor analysis. The fraction of cells with mutations may have been too low in order for detection by the 
Surveyor analysis.  
In summary, both OCT-N and OCT-Dn efficiently induce indels at the on-target site, while not affecting off-
targets in HEK293 cells. All NANOG-CRISPRs lack efficient induction of indels at the on-target site and off-
target effects are not observed either. This could either be explained by mistakes that happened during the 
experiment or the inefficiency of the gRNAs targeting NANOG in guiding the Cas9 protein. However, the 
concept that the CRISPRs are both efficient at the on-target site and lack off-target activity was proven 
through the OCT4-CRISPR. Considering that the NANOG- and OCT4-CRISPRs were designed on the same 
guidelines, time that would have been spend on repeating the assay and testing different gRNAs was 
instead used for testing the effectiveness of the already designed NANOG-CRISPRs in the hESC system.  
Figure 12: OCT4-CRISPRs but not NANOG-CRISPRs induce mutations at the on-target site in HEK293 cells. Sequencing of 
subcloned PCR products obtained from genomic DNA of HEK293 cells transfected with either double nickases (Dn) or a nuclease 
(N) targeting NANOG or OCT4 reveal that mutations are efficiently generated close to the OCT4, but not the NANOG stop codon 
(coding sequence is marked in yellow). The most common mutations are deletions from 1 to 46 bp, while there is a single 
insertion of 1 bp and a single point mutation. The expected cut or nick sites are marked with vertical lines. 
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Table 5: CRISPR off-targets. In silico Off-target (OT) analysis is performed with the CRISPR design webtool of Zhang´s lab [251]. 
Only the ten most likely OTs are considered and the priority is given to off-target sites within pseudogenes (pseudo) of OCT4 and 
NANOG. The OT score (0-100) calculation is based on an algorithm that considers the number of mismatches of the OT sequence 
to the guide sequence and the position of the mismatches (where 1 is adjacent to the PAM sequence). For the off-target analysis 
the regions containing the on-target and off-target sites are PCR-amplified and digested (Figure 13, Figure 20). Here the lengths 
of the PCR products and the approximate lengths of the digested PCR products are listed. 
 
 
 
Figure 13: OCT4-CRISPR induce mutations at on-target but not off-target sites in HEK293 cells. The sensitivity of the Surveyor 
assay was tested by mixing two DNA sequences that only deviated with a single bp in various ratios, showing that 3 % mutated 
DNA can potentially be detected (A). Surveyor analysis is performed on PCR products obtained from genomic DNA of HEK293 
cells that were either non-transfected (negative control - Ctrl) or transfected with double nickases (Dn), a nickase (n), or a 
nuclease (N) targeting OCT4 (B, C) or NANOG (D, E). The amplified sequences contain the on-target sequences and the most likely 
off-targets that are within OCT4 or NANOG pseudogenes (P). Due to single nucleotide polymorphisms several bands can appear 
on the gel. Hence, the negative control is essential to reveal the background band pattern of each PCR product. The expected 
band lengths of the PCR products and the approximate expected band lengths of the Surveyor digested PCR product in the case 
of CRISPR-induced mutations are listed in Table 5 and the expected band lengths are indicated by arrow heads. Mutations are 
efficiently generated at the OCT4 on-target site (red arrow heads), but not at OCT4 off-target (OT), NANOG on-target or NANOG 
off-target sites (black arrow heads). However, some mutations might be masked (blue arrow heads), since bands of the expected 
lengths are also present in the negative control. 1 kb plus DNA Ladder (Invitrogen) was used.  
Gene OT, OT score & position of mismatches Pseudo PCR (bp) ~ Dig. PCR (bp) 
NANO N2 N1/DnA DnB
 1 100 0 1 100 0 1 100 0 P8 3928 927+3001 
 2 26.8 15 6 5.9 1;17 5 2.3 5;15 P7 3260 2764+496 
 3 14.9 14 - - - - - - P9 1865 690+1175 
 4 3.7 4;12 2 100 0 2 100 0 P1 2620 690+1930 
 5 3.7 4;12 3 100 0 3 100 0 P1 2911 578+2333 
 6 3 2;15 - - - - - - P2 3911 1489+2422 
 9 1.4 3;14 - - - - - - P10 3785 2609+1176 
 10 1.3 4;14 - - - - - - P4 2903 900+2003 
 - - - 4 38.5 17 - - - P5 2618 2176+442 
 - - - - - - 8 0.8 2;9;17 P6 1696 903+793 
OCT4 N DnA DnB
 1 38.5 17 - - - - - - P5 2980 558+2538 
 2 38.5 17 - - - 1 100 0 P3 3100 725+2375 
 3 2.5 10;17 2 17.2 16 4 5.7 1;17 P4 3903 2978+725 
 4 1.8 9;17 - - - - - - P6 3198 1613+1585 
 - - - 1 17.2 16 6 2.4 9;20 1b 1741 515+1226 
NANO On-target (primer 51, 52) 3806 2400+1406
 On-target (primer 53, 54) 2143 685+1458 
OCT4 On-target 2935 1644+1291 
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3.3. Derivation of fluorescent reporter lines 
3.3.1 OCT4-mCHERRY and NANOG-VENUS reporter lines are derived with 
high absolute and relative targeting efficiency 
HuES4 hESCs were co-transfected with CRISPR vectors and linearized pNV or pOC, and homologously 
recombined clones were selected with G418 (neomycin) or hygromycinB. The recombineering is facilitated 
by CRISPR-induced double-strand breaks close to the insertion site at the stop codons (Figure 7). The hESC 
colonies were expanded and fluorescence microscopy of live cells confirmed expression of the transgenes 
from both NV and OC clones (Figure 14). 
The expanded colonies were genotyped by amplifying genomic DNA of the target loci (Figure 15). Correct 
insertion at the 5´ side and 3´ side were validated, and the existence of a wt OCT4 or NANOG allele was 
confirmed. When the transgene was not correctly targeted it was tested whether the reporter had 
randomly integrated by amplifying a sequence within the transgene. Additionally estimations of the 
absolute and relative targeting efficiencies were based on the genotyping.  
The targeting efficiencies for a SOX17-GFP reporter line derived in our lab by conventional gene targeting 
are listed as a reference (Table 6). In the SOX17 reporter line the GFP transgene is inserted immediately 
downstream of the start codon, and homologous recombination depends on 60kb and 3.5 kb HAs. 
Additionally the antibiotic resistance gene, neomycin phosphotransferase, is expressed from a SV40 
promoter. 
 
Figure 14: OC and NV clones express mCHERRY and VENUS, respectively. Live fluorescence microscopy images of OC clones (OC-
N-3, OC-Dn-6) (A), and NV clones (NV-N2-6, NV-N1-3) (B). 
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The following speculations on targeting efficiencies are based on one experiment. It remains to be shown 
whether the results are reproducible. 
The relative targeting efficiencies are high for all cell lines, ranging from 50 % to 100 % (Table 6), which is 
likely attributable to the promoter trap approach used in the NV and OC reporters or the long HAs used for 
the SOX17-GFP reporter derivation. In SA121 and H9 cell lines the SOX17-GFP reporter were derived with 50 
% efficiency, while 100 % efficiency was achieved in the HuES15 cell line. This divergence likely reflects 
different sensitivities of the cell lines for G418 treatment. The relative targeting efficiency for the CRISPR-
aided derivation of NV and OC reporters also ranges from 50 % to 100 %, with an average of 86 %. However, 
4 out of the 6 incorrectly targeted clones likely only contain a minor insert of the reporter plasmid at the 3´ 
end, as indicated by the longer PCR product of these clones (Figure 15). There is a trend for a lower 
efficiency of the derivation of the OC reporter. However, more clones would need to be analyzed to obtain a 
statistically powerful result. The circumstance that the 3´UTR of NANOG, but not of OCT4 extends past the 
end of the 3´HA would offer an explanation for, why insertions downstream of the 3´HA of NANOG occur 
less frequently. NANOG expression might be perturbed by an insertion downstream of the 3´HA due to 
improper termination of the transcript or disruption of other important regulatory sequences. 
The OC and NV reporter lines could be derived with all CRISPRs, with an average absolute targeting 
efficiency of 3.2x10-5 (Tablr 6). The average targeting efficiency was in average more than 2 times higher for 
the OC reporter. Many factors could have influenced the absolute targeting efficiency. It might be 
attributable to differences in the positive selection strategies. A minimal lethal concentration for G418 
(neomycin) and hygromycinB was not determined, and instead standard concentrations used in the 
derivation of PSC reporter lines were used. After 5 days of antibiotic treatment the appearing NV colonies 
selected with hygromycinB were smaller than the OC colonies selected with G418, suggesting that G418 
treatment was less harsh on the cells. Subsequently, the concentration of hygromycinB was reduced. It is 
likely that some targeted clones have not survived the selection. Even if the same antibiotic resistance 
genes would have been used, differences in expression levels at the targeted loci could have influenced the 
outcome. Another factor affecting the absolute targeting efficiency could have been the occurrence of 
genomic deletions between NANOG and NANOGP1. Those deletions would prevent homologous 
recombination. Finally, the PCR amplification of the 3´HA of NANOG and subsequent sequencing revealed 
that the 3´UTR of NANOG is heterogenous. Some alleles have a 22 bp insert 310 bp downstream of the stop 
codon (data not shown). The PCR product was subcloned and 4 out of 5 subclones contained the insertion. 
To ensure homology with as many alleles as possible, the insertion was included in the HA. However, the 
alleles that do not contain the insert will likely only align with the first 313 bp of the HA, which probably 
decreases the efficiency of homologous recombination for those alleles. 
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Table 6: Targeting efficiencies obtained with conventional or CRISPR-aided recombineering. A SOX17-GFP (SG) reporter cell line 
was produced without the CRISPR-Cas9 technology by transfecting (BioRad electroporation) a reporter construct with a 60kb 
5´HA and 3.5 kb 3´HA. OC and NV reporter lines were produced with short HAs (0.7 kb) and the aid of CRISPR nucleases (N) or 
double nickases (Dn) targeting the insertion site. Only few of the growing clones (grow) were expanded and analyzed (exp) in 
the derivation of the OC and NV reporter lines. The relative targeting efficiencies (Rel targ effic) are calculated as the percentage 
of correctly targeted clones from analyzed clones, and the absolute targeting efficiency is calculated as the fraction of correctly 
targeted clones from transfected cells, where the relative targeting efficiency is used to obtain an estimate of correctly targeted 
clones within the pool of growing clones. The numbers in brackets include clones that are correctly targeted at the 5´ side, but 
contain a minor insertion at the 3´side. Abbreviations: Rel targ effic - relative targeting efficiencies; Abs targ effic - absolute 
targeting efficiencies 
Reporter 
line  
hESC 
line  
Transfected 
(106 cells) 
CRISPR  Clones 
grow/exp 
Trans-
genic  
Tar-
geted  
Rel targ 
effic (%) 
Abs targ 
effic (10-6) 
SG  SA121  50   40 40 34  21  52  0.42 
 H9  50   10 10 8  5  50 0.1 
 HuES15  50   5 5 5  5  100 0.1 
Total 150  55 55 47 31 56 0.37 
OC HuES4 2  N 142 5 4  4  80 56.8 
 HuES4 2  Dn  120 6 6  3 (5) 50 (83) 30 (49.8) 
NV HuES4 2  N1  57 10 10  10  100 28.5 
 HuES4 2  N2  21 8 8  8  100 10.5 
 HuES4 2  Dn  42 6 6  5 (6)  83 (100) 17.5 (21) 
Total 10  382 35 34 30 (33) 86 (94) 32 (36) 
OC-NV HuES4 10  N+N1  - - -  - - - 
 
 
Figure 15: Genotyping reveals high relative targeting efficiencies of the mCHERRY-Neomycin VENUS-Hygromycin transgenes. 
Correct targeting of the mCHERRY-Hygromycin and VENUS-Hygromycin transgenes to the stop codons of OCT4 (B) and NANOG 
(C), respectively, were assessed for expanded OC and NV clones. A schematic of the locations of the primers used for genotyping 
is shown (A), where primer 1 + 3 and 2 + 4 are used for assessing the correct insertion at the 5´ end and the 3´ end, respectively. 
Primer 2 and 3 were used to assess random insertion in to the genome (transgenic) and primer 1 and 4 to assess the existence of 
non-modified OCT4 or NANOG alleles (heterozygosity). Except OC-N4 all clones have a transgene within their genome. All other 
clones are correctly targeted at the 5´ end, but 3 clones have an unexpected insert at the 3´ end (OC-Dn2-3 and NV-Dn3), and 1 
clone is not correctly targeted at the 3´ end  (OC-Dn1). The GeneRuler 1 kb DNA ladder (Fisher Scientific) was used.  
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There are minor differences in the absolute targeting efficiencies between the different CRISPR vectors. This 
is expected due to inherent differences in the capacity of gRNAs to induce the Cas9-mediated cuts [273] and 
the use of either the nuclease or double nickase strategy, where the latter might be less efficient in inducing 
HDR [14]. This is reflected in the lower efficiency of both NANOG and OCT4 double nickases compared to 
the nucleases. Additionally the distance between the insertion site and the induced double-strand break is 
variable between the different CRISPRs. For efficient gene targeting the CRISPR needs to cut as close as 
possible to the integration site [14]. Therefore it was expected that the most distal NAN-N2 is less efficient 
than NAN-N1 in facilitating gene targeting (Table 2, Figure 10). NAN-N1 was almost 3 times as efficient as 
NAN-N2.  
The absolute targeting efficiency obtained with the CRISPR technology is about 100 fold higher than what 
typically is obtained without a DNA cutting tool (Table 6)[37]. However, the increase in targeting efficiency is 
not simply attributable to the use of the CRISPR technology. Other factors in the targeting procedure such 
as differences in the electroporation system [222, 224], the HA lengths [12], the positive selection strategy, 
and the cell lines chosen (Table 6) can have considerable effects on the absolute targeting efficiency. 
Nevertheless, while the results do not allow precise conclusion on the magnitude of the CRISPR-Cas9 effect 
on the absolute targeting efficiency, the results clearly indicate that the CRISPR-Cas9 system drastically 
increases the absolute targeting efficiency above the level that can be obtained even with long HAs, but 
without a DNA cutting tool. 
Additionally, the complete reporter construct of the clones NV-N1-1 and OC-Dn-5 were 
analyzed by Sanger sequencing to confirm the correct targeting of and the lack of mutations in the reporter 
cassettes. The reporter cassettes contained no mutations and were correctly targeted at both the 3´ and 5´ 
end (data not shown). This confirms the PCR-based genotyping and the feasibility of using short HAs to 
facilitate accurate targeting of large transgenes.  
3.3.2. The absolute targeting efficiency is not sufficient for a double 
reporter production in one step 
The ability to target two transgenes to specific genomic loci simultaneously would save researchers months 
of work, whenever it is necessary to create a model with multiple genomic modifications. With the increase 
in absolute targeting efficiency obtained due to the CRISPR-Cas9 system, it might be possible to target 
multiple genes or both alleles of one gene simultaneously. In fact, in HEK293 cells two alleles of one gene 
were successfully targeted [276], and with short single-stranded oligos homologous recombination 
efficiencies of above 1 % were achieved in hESCs [14]. Therefore it is tempting to speculate that sufficiently 
high recombination efficiencies can be achieved as well with long transgenes in hESCs. 
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The NV and OC reporter constructs were designed to allow a combination of the reporter lines; the 
fluorescence proteins VENUS (green) and mCHERRY (red) do not significantly overlap in their fluorescence 
spectra and positive selection is based on different antibiotics. 10 million cells were transfected with 
linearized pOC, pNV as well as the most efficient CRISPRs from the single reporter derivation (Table 6).  
An OC-NV double reporter was not obtained. This was not unexpected considering the absolute targeting 
efficiencies obtained in the single reporter derivation. Assuming that the probability of the recombination 
event is the same in each transfected cell and that the OC and NV recombination events are independent of 
each other, the expected absolute targeting efficiency of a double reporter line is is 1.6x109 (56.8x106 * 
28.5x106) or approximately 1 clone in every 400 million transfected cells. The expected targeting efficiency 
is probably an underestimate, since a lot of the transfected cells died during the transfection, and therefore 
the assumption of equal probabilities in each cell is not given. However, even if we assume that half of the 
cells die during the transfection and thereby double the efficiencies of each recombination event, still only 1 
OC-NV clone would appear in on average every 100 million transfected cells. Hence, the system must be 
optimized to obtain higher absolute targeting efficiencies in order to permit targeting two transgenes in 
hESCs simultaneously, or extremely high numbers of cells need to be transfected.  
3.4. OCT4-mCHERRY and NANOG-VENUS reporter line 
characterization 
3.4.1. mCHERRY and VENUS faithfully report OCT4 and NANOG expression 
The most important property of a reporter cell line is that the reporter gene faithfully reports expression of 
the gene of interest. Immunofluorescence analyses were performed to assess whether OCT4 and NANOG 
are co-localized with mCHERRY and VENUS, respectively. Fluorescence microsocopy of live OC and NV cells 
have revealed that the fluorescence of the reporter lines is dim (Figure 14). In order to obtain a stronger 
fluorescence to enable a clear distinction of positive and negative areas, mCHERRY and VENUS are stained 
as well. 
The OC reporter line shows a high degree of OCT4 and mCHERRY co-expression (Figure 16). However, some 
cells stain for mCHERRY but not for OCT4. Those cells seem to be dying, and e.g. in FACS analyses those cells 
are not considered anyway. Additionally, although the staining intensity of mCHERRY was strongest in the 
nucleus, some mCHERRY seems to be present in the cytoplasm as well. OCT4 can shuttle in and out of the 
nucleus [318]. However, it is unlikely that the cytoplasmic mCHERRY stain is a consequence of partly 
cytoplasmic OCT4, since the OCT4 stain is exclusively nuclear. Further immunofluorescence analysis using 
other antibodies against mCHERRY or without staining mCHERRY need to be performed to obtain clarity. 
Results 
59 
 
 
Figure 16: mCHERRY and VENUS are coexpressed with OCT4 and NANOG. Immunofluorescence analysis of OC (A) and NV (B) 
clones (only OC-Dn-5 & NV-Dn-2 shown) reveal that mCHERRY (mCH) and VENUS (VEN) are coexpressed with OCT4 and NANOG 
(NAN). However, the mCHERRY stain was not exclusively nuclear; in the close-up the lowest arrow marks cytoplasm that was 
faintly stained. The remaining 3 arrows mark dying cells that were strongly stained for mCHERRY, but negative for NANOG. 
VENUS was co-localized with both NANOG and OCT4. Rarely cells were observed in the stainings that were positive for NANOG, 
but negative for VENUS (marked by an arrow), while the opposite was not seen. Intriguingly, the marked cell was not expressing 
OCT4. Abbreviations: BF – bright-field 
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Figure 17: Expression of VENUS is lost together with expression of NANOG upon spontaneous and forced differentiation. 
Immunofluorescence analysis of spontaneously differentiated cells (A) and cells differentiated with a 3-day DE protocol (B, C) 
reveal that expression of VENUS (VEN) is lost together with NANOG (NAN). In A the arrows mark neighboring cells that look 
similar morphologically, but the left cell was not expressing the pluripotency factors OCT4 and NANOG, which was faithfully 
reported by VENUS. Upon DE differentiation some cells differentiated to DE as indicated by the expression of the DE marker 
SOX17, some remained pluripotent as marked by NANOG and others were in intermediate phases expressing both SOX17 and 
NANOG, where the intensities of SOX17 and NANOG stainings were inversely related. The left arrow marks a cell with weak 
SOX17 and strong NANOG intensity, the middle arrow a cell with strong SOX17 and intermediate NANOG intensity, and the left 
arrow a cell with strong SOX17 and weak NANOG intensity. The intensities of the NANOG and VENUS stainings coincided 
convincingly. There is noise in the VENUS (A) and SOX17 (B) stain. Abbreviations: BF – bright-field; PH – phase contrast. 
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The NV reporter line shows a high degree of NANOG and VENUS co-expression as well (Figure 16). Only 
sporadically cells were observed in the stainings that were NANOGpos and VENUSneg, while the opposite was 
not seen. Expression of OCT4 in the NV cell line indicates that pluripotency is maintained when VENUS is 
targeted to the C-terminus of one allele of NANOG. OCT4 and NANOG are considered to be at the core of 
the pluripotency transcription factor network, and the expression of both markers is a good indication for 
pluripotency [23].  
Spontaneous differentiation occurred rarely under pluripotency-supporting culture conditions; in the 
immunofluorescence analysis only one well with a considerable fraction of spontaneously differentiated 
cells was recognized (Figure 17). Loss of the pluripotency factors OCT4 and NANOG was reflected with loss 
of VENUS in the NV reporter. Hence, the NV reporter can be used to isolate pluripotent cells from 
spontaneously differentiated cells. 
To get an indication of whether the fusion protein reporter enables exact monitoring of the gene of interest, 
NV hESCs were differentiated with a widely used DE differentiation protocol [305] and analyzed by staining 
for NANOG, VENUS and the DE marker SOX17 (Figure 17). A mixed population of differentiated and 
undifferentiated cells were obtained, as indicated by the expression of SOX17 or NANOG. Some cells co-
expressed SOX17 and NANOG, where the intensities of SOX17 and NANOG stainings were inversely related. 
These cells are likely in intermediate developmental stages. Importantly, the staining intensities of NANOG 
and VENUS coincide convincingly, where strong, intermediate and weak expression of NANOG in individual 
cells was faithfully reflected by VENUS. Since it was not a confocal analysis, conclusions about the absolute 
expression levels cannot be drawn based on the staining intensities. However, it is clear that VENUS 
expression follows NANOG expression closely. 
3.4.3 T2A self-cleavage is highly efficient 
2A self-cleaving peptides allow expression of multiple genes from one promoter. To permit unperturbed 
functioning of the upstream and downstream proteins the self-cleavage of the 2A peptide needs to be 
highly efficient. To address the cleavage efficiency of the T2A peptide that separates VENUS and 
HYGROMYCIN-B KINASE as well as mCHERRY and NEOMYCIN PHOSPHOTRANSFERASE western blots for 
NANOG and mCHERRY were performed in NV and OC clones, respectively. Four clones were analyzed and 
comparatively faint bands for the non-cleaved protein were present. The cleavage efficiency was 
approximately 94 %, as estimated based on the relative intensities of the protein bands (Figure 18). The T2A 
self-cleavage efficiency was highly homogenous between the 4 clones. It is not expected that the 6 % non-
cleaved protein will have an effect on the function of NANOG or OCT4. 
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Figure 18: HYGROMYCIN-B KINASE and NEOMYCIN  PHOSPHOTRANSFERASE are cleaved off the fusion proteins with 94 % 
efficiency. Proteins were extracted from NV (N1-1, N1-2, N2-2) and OC (Dn-5) clones and western blots were made for NANOG 
(A) or mCHERRY (B), respectively. Bands with the expected lengths of NANOG-VENUS-HYGROMYCIN-B KINASE (NAN-VEN-HYG) 
and NAN-VEN, or OCT4-mCHERRY-NEOMYCIN  PHOSPHOTRANSFERASE (OCT4-mCH-NEO) and OCT4-mCH were present in the 
reporter clones but not in the non-modified parental cell line (ctrl). The combined intensities of these bands were estimated 
with the Image Lab software and the cleavage efficiency is shown as the percentage of the intensity of the NAN-VEN or OCT4-
mCH bands from the combined intensity (C). The T2A self-cleaving peptide cleaves itself with consistently high efficiencies that 
range from 93 % to 95 %. Approximate molecular weights in kDa: NAN - 36; NAN-VEN - 63; NAN-VEN-HYG - 103; OCT4 –mCH - 70; 
OCT4-mCH-NEO - 100.  
3.4.4. CRISPRs induce mutations in non-targeted allele and in the targeted 
allele when the PAM sites are not mutated 
The CRISPR-Cas9 system induces double-strand breaks with high efficiency. Hence, it is expected that both 
alleles of NANOG or OCT4 are targeted and that the majority of the derived clones contain indels at the 
non-targeted allele. Since one of the nickases of the double nickase pairs produce a nick within the coding 
sequence (Figure 10) there might even be frame shift mutations.  
To assess whether mutations are induced in the non-targeted allele, the CRISPR target sites in 6 NV (N1-1, 
N1-2, N2-2, N2-6, Dn-1, Dn-2) and 5 OC (N-1, N-3, Dn-2, Dn-4, Dn-5) clones were analyzed by Sanger 
sequencing. 10 out of the 11 analyzed clones contain a single mutation or multiple mutations at the CRISPR 
cut sites in the non-targeted alleles (Figure 19). Multiple mutations may have been induced by consecutive 
cuts in the same sequence; as long as mutations do not obstruct the target region there is no hindrance for 
the CRISPR-Cas9 system to recognize the same site several times. 7 of the analyzed clones contained a 
clonal non-targeted allele while 4 clones had a mixture of non-cut and cut alleles. The mutations in the 
latter clones must have occurred in cell cycles subsequent to the recombination event. The existence of two 
or several different alleles complicates the interpretation of the sequencing data. Clonal analysis of the PCR 
product is necessary to precisely locate the mutations that have occurred in those clones. All analyzed OCT4 
clones contained frame shift mutations, resulting in a delayed stop codon. These results stress the 
importance to locate the CRISPR cut sites outside of the coding sequence and other known regulatory 
sequences to prevent frame shift mutations and unwanted confounding effects.  
Additionally, the sequencing revealed that there were point mutations in the 3´UTR of OCT4. Since these 
were present in most clones, it is likely that were not induced by the CRISPR-Cas9 system, but instead  
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Figure 19: The nontargeted allele of OCT4 or NANOG contains mutations in 10 out of 11 clones. The CRISPR target region of OC 
(A) and NV (B) clones was PCR-amplified, gel-purified and sequenced. 10 out of 11 analyzed clones contain a mutation or several 
mutations, generally close to the expected CRISPR cut site (marked with vertical lines). OC-N-1 and OC-N-3 are exceptions, in 
that mutations occur already far upstream of the expected cut site. Deletions (green arrows) are contained in seven clones (OC-
N1, OC-Dn2, OC-Dn-4, OC-Dn5, NV-N1-2, NV-N2-6, NV-Dn2), small insertions (blue arrows) in three clones (OC-N-3, NV-N1-1, NV-
Dn-2) and point mutation(s) in 8 clones (OC-N-1, OC-N-3, OC-Dn-4, OC-Dn-5, NV-N1-1, NV-Dn-1, Nv-Dn-2). While the coding 
sequence is unaffected in the NV clones, all OC clones contain frame shift mutations. The mutations are either clonal (OC-Dn2, 
NV-N1-1, NV-N1-2, NV-N2-6, NV-Dn-1, NV-Dn-2), or occured in a subset of the cells (OC-N-1, OC-N-3, OC-Dn2, OC-Dn-4, OC-Dn-5; 
the analyzed PCR product of OC-Dn4 was clonal, but the agarose gel contained two bands (Figure 15), suggesting that a non-
mutated or differently mutated non-targeted OCT4 allele was also present in the cell population. No sequence read was 
obtained from the longer PCR product of OC-Dn4.). There are three point mutations in the 3´UTR of OCT4 in most analyzed 
clones, suggesting that they have existed in the parental hESC line (purple). 
already existed in the parental hESC line. These mutations are within the seed sequence of OCT-N and 
within the distal part of OCT-DnB. It is remarkable that the absolute targeting efficiency achieved with OCT-
N was the highest among all CRISPRs despite of the mismatches in the seed sequences that probably have 
existed in at least a subset of the transfected cells. In order to prevent mismatches of the generated CRISPRs 
to the target sequence, it would be necessary to sequence the target region in the parental cell line. The 
empirically determined sequence could be used instead of the annotated genomic sequence as the basis for 
the CRISPR design. 
As previously discussed the PAM sequences can be mutated to avoid mutations in the targeted 
allele [236, 241]. In fact, the PAM sequences for OCT-DnA (TGG→TGA) and OCT-N (TGG→TGT) have been 
mutated and the NAN-DnB recognition site is disrupted by insertion of the transgene. Hence, it is expected 
that only NAN-Dn-A, NAN-N1, NAN-N2 or OCT-DnB may induce mutations in the targeted allele. 
Furthermore, single nickases usually induce indels with low efficiencies [14, 15, 252, 255]. Since only one of 
the two double-nicking CRISPR target sites remains intact in the targeted allele of both NANOG and OCT4, it 
is unlikely that mutations are produced with the double-nicking strategy. Therefore mutations in the 
targeted allele are likely only in NV-N1 or NV-N2 clones. To assess whether mutations are induced in the 
targeted allele, the CRISPR target sites of the clones NV-N1-1 and OC-Dn-5 were assessed by Sanger 
sequencing. As expected there was a mutation in the 3´UTR of the analyzed NV clone at the cutting site of 
N1 (clonal 17 bp deletion; data not shown). In contrast, the OC-Dn clone had not acquired mutations. These 
results indicate that also the targeted allele is subjected to CRISPR-induced mutations, but that mutating 
the PAM sequence prevents Cas9 from inducing double-strand breaks. Analyzing further clones would be 
necessary to confirm these findings. 
3.4.5. CRISPRs targeting NANOG induce mutations in NANOGP8 
As mentioned previously, off-target effects remain a major concern in the use of the CRISPR-Cas9 system, 
and there are deviating accounts of the extent of the CRISPR off-target activity. Surveyor analysis is 
performed on one clone of each CRISPR (OC-N-3, OC-Dn5, NV-N1-1, NV-N2-2, NV-Dn-2) to assess whether 
mutations have been induced at the most likely off-target sites of the used CRISPR.  All analyzed off-target 
sites are within pseudogenes of NANOG and OCT4 (Table 5). NANOGP1 has two perfectly homologous 
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sequences to the target sequence of NAN-N1/NAN-DnA and NAN-DnB, and NANOGP8 contains a precise 
match to the target sequences of NAN-N2, NAN-N1/NAN-DnA and NAN-DnB. These loci are expected to be 
cut and subsequently mutated due to NHEJ. Most other off-targets have one or two mismatches and 
mutations may occur at those sites.  
Surprisingly, off-target mutations were only found in NANOGP8. However, results for one of the perfectly 
homologous sequences within NANOGP1 were not obtained. Nevertheless mutations were expected to 
occur within the other site of NANOGP1 with perfect homology to the NAN-N1/NAN-DnA and NAN-DnB 
target sequences. Perhaps the paternal HuES4 cell line has mutations within NANOGP1 that rendered the 
sequence of the off-target site. Alternatively, there is the chance that none of the alleles were mutated or 
the result was a false negative. Furthermore, mutations at 4 off-targets (NANOGP4 and OCT4P3-5) might  
 
Figure 20: All CRISPRs targeting NANOG induce mutations in NANOGP8. Surveyor analysis is performed for 2 OC (N-3 and Dn-5) 
and 3 NV clones (N1-1, N2-2, Dn-2) for the most likely off-targets (OTs) within OCT4 (B) and NANOG (D) pseudogenes (P). As a 
positive control, Surveyor is performed for the on-target sites (A,C) (By sequencing it was confirmed that mutations occurred at 
the on-target sites for all clones except NV-N2-2; Figure 19). The expected band lengths of the PCR products and the 
approximate expected band lengths of the Surveyor digested PCR product in the case of CRISPR-induced mutations are listed in 
Table 5 and the expected band lengths are indicated by arrow heads. As expected mutations were detected at the on-target site 
in all clones (red arrow heads) except in NV-N2-2 (black arrow head). At off-target sites mutations have only been detected in 
NANOGP8. However, some mutations might have been masked, since bands of the expected lengths are also present in the 
negative control (blue arrow heads). There is no data in one of the NANOGP1 sites for the analyzed NV-N1 and NV-Dn clone. 
GeneRuler 1 kb and 100 bp plus DNA ladders were used. 
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have escaped detection, since bands with the expected lengths are present in the negative control. This 
highlights one of the weaknesses of the Surveyor assay in that the assay is not suited for detection of 
mutations, when there is a polymorphism in proximity to the cut site. In general the Surveyor analysis 
suggests that off-target effects are not a major concern in the context of this study, where 2 million hESCs 
are nucleofected with 5 µg pX330 or 2 x 2.5 µg pX335 in the nuclease and double nickase strategy, 
respectively. However, deep sequencing would be necessary to rule out false negative results obtained in 
the Surveyor assay.
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4. Discussion 
hPSCs are an invaluable tool for studying human embryonic development with great potential for drug 
development as well as cell replacement therapies. Progress in hPSC-based research was greatly hindered 
by the difficulty of genetically modifying hPSCs. With the technological advances of ZFNs and TALENs the 
efficiency of gene targeting in hPSCs were increased by several orders of magnitude [16, 17, 215, 216], but 
the production of the ZFN and TALEN tools themselves is time-consuming. In contrast, the CRISPR-Cas9 
genetic engineering tool is assembled within days [19]. In this study the practicality of using the CRISPR-
Cas9 system from S. pyogenes in the production of hESC reporter lines was tested. 
4.1. Human embryonic stem cell reporter production with CRISPR-
Cas9 
hPSC fluorescent reporter lines are an important tool in hPSC-based research [8, 10, 66]. Gene targeting is 
generally regarded superior to random integration for the production of reporter lines due to preserving the 
epigenetic and regulatory genomic environment [208]. Gene targeting in hPSCs were traditionally a tedious 
process and a wide variety of strategies have been explored [12, 208]. Here a strategy involving fusion of 
the endogenous and fluorescence genes, a promoter trap and the CRISPR-Cas9 system was applied in order 
to rapidly produce faithful hESC reporter lines.  
Molecular cloning was traditionally based on the action of restriction enzymes and the 
assembly of several DNA segments required consecutive cloning steps [313, 314]. In contrast Seamless 
cloning allowed the assembly of four DNA fragments to the NV and OC reporter plasmids in a single cloning 
step. The procedure depends on short homologous regions at the ends of the DNA fragments (here 18 bp) 
that were generated by primer overhangs or incorporated to the sequence of synthesized DNA blocks. 
Seamless cloning proved to be a time-saving cloning strategy that enabled simultaneous and directional 
ligation of four DNA fragments independent of restriction sites and without leaving restriction scars. 
Previous reporter lines were often characterized by heterozygosity in the targeted gene [8, 
220], and it is difficult to prove haplosufficiency of a gene. Therefore it is preferable to produce reporter 
lines that do not disrupt the endogenous gene [208]. In the NV and OC reporter lines NANOG and OCT4 
were targeted upstream to the stop codon, and NV and OC fusion proteins are translated from the targeted 
allele. An obvious pitfall with fusion proteins is an interaction between the proteins or a steric hindrance 
that interferes with the function of the protein. The NV and OC reporter lines retained a normal 
morphology over more than 10 passages and remained pluripotent as judged by immunostaining of OCT4 
and NANOG. Hence, a dominant negative effect on the endogenous protein can be excluded, since 
perturbation of OCT4 and NANOG would be accompanied by loss of pluripotency or an increased 
propensity for differentiation, respectively [41, 286]. It cannot be excluded that the targeted allele of 
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NANOG or OCT4 is perturbed. However, perturbation of NANOG due to fusion to a fluorescence gene is 
unlikely, since both alleles of NANOG were previously targeted in mESCs without altering the proliferation 
rate, morphology or the capacity for tetraploid chimera complementation [296]. Another gene targeting 
strategy that is unlikely to perturb the endogenous protein and does not depend on fusion proteins is 
expression of the fluorescence gene from the endogenous protein via an IRES or T2A sequence is [12, 17].  
Another implication of using fusion proteins is that the stability of the endogenous and the fluorescence 
protein may change due to the fusion. Fluorescent proteins have long half-lives and the signal will remain 
long after the loss of the endogenous protein, which hinders the study of transiently expressed 
developmental regulators [309]. Furthermore studies into the involvement of NANOG and OCT4 in early 
mesendodermal and endodermal development necessitate reporter lines that precisely report the 
dynamics of NANOG and OCT4 during the exit of pluripotency. Since the fluorescent protein is fused to the 
endogenous protein, the fluorescent protein can only be present in cells that also contain the endogenous 
protein. A pitfall associated with fusion proteins is the possibility that the half-life of the endogenous 
protein is increased due to fusion to the fluorescent protein and that the reported dynamics are an artefact. 
A study with a Nanog-VENUS, Nanog-KATUSHKA mESC reporter line showed that the half-lives of the fusion 
proteins were identical to the half-life of Nanog, indicating that the aminoterminal endogenous protein 
determines the half-life [296]. Immunocytochemical analyses of the NV reporter showed that only a 
minuscule number of NANOGpos, but VENUSneg cells exist in pluripotency and during differentiation, which 
indicates that the stability of the NV fusion protein is similar to or higher than that of NANOG. Little can be 
concluded from the analysis of the OC reporter, since mCHERRY staining was present in some OCT4neg dying 
cells and weakly present in the cytoplasm while OCT4 staining was restricted to the nucleus. These findings 
are paradox, because mCHERRY is fused to OCT4, and instead suggest background staining. Further analyses 
are required to confirm that mCHERRY is strictly co-localized with OCT4. However, determination of 
whether or not the stabilities of the fusion proteins are identical to the endogenous proteins ultimately 
requires empirical assessment of the half-lives. Using pest sequences to reduce the half-lives of fluorescent 
proteins may eliminate the risk that the stability of the endogenous protein is altered [319]. On the other 
hand the stabilities of the endogenous and the pest-tagged fluorescent proteins are unlikely identical, and a 
reporter may still be imprecise. 
An advantage of fusion proteins is that the subcellular localization of the endogenous protein is reported. 
Knowing the subcellular localization is useful for factors which activity is dependent on a certain subcellular 
localization such as transcription factors and polarity-associated proteins. Additionally, nuclear fluorescence 
as a consequence of nuclear localization of NANOG and OCT4 in pluripotency helps discerning between two 
cells in close proximity [17]. This would facilitate automated quantifications of microscopy-based 
experiments using the NV and OC reporter lines [227]. 
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As long as absolute targeting efficiencies in hPSCs remain low, a positive selection mechanism is 
required to enable derivation of reporter lines. The positive selection marker is typically an antibiotic 
resistance gene and can either be driven by the endogenous promoter in a promoter trap or by an 
exogenous promoter. Due to interference with the endogenous promoter, the exogenous promoter needs 
to be excised in a time-consuming procedure after the production of the reporter line [208]. Furthermore 
low relative targeting efficiencies of less than 0.5 % are typically achieved with exogenous promoters, since 
randomly integrated transgenes express the selection marker as well [8, 37]. Hence, extensive screening for 
correctly targeted clones is required despite the use of a positive selection marker. In this study a promoter 
trap was used and the relative targeting efficiency was in average 86 %. Thus the promoter trap approach 
reduces the number of clones that need to be screened. Furthermore it was shown that the T2A self-
cleaving peptide is a feasible strategy for multicistronic expression, though around 6 % of the protein 
remains uncleaved as estimated by western blot analysis. Considering the reported differences in 
expression of genes upstream and downstream of IRES sequences and the altered stability of the mRNA due 
to the presence of the IRES sequence [301, 311], 2A self-cleaving peptides appear the more attractive 
strategy for multicistronic expression.  
The promoter trap strategy is limited to factors that are expressed in pluripotency, excluding many 
developmental regulators. Since the CRISPR-Cas9 system alerts the DNA repair machinery to the insertion 
site, the CRISPR-Cas9 system itself may increase the relative targeting efficiency. Furthermore higher 
relative targeting efficiencies may be achieved with long HAs, though at the expense of complicating the 
cloning procedure [213]. E.g. the average relative targeting efficiency achieved in our lab in the production 
of a SOX17-GFP reporter using 3.5 kb and 60 kb HAs were 56 % (Karen Schachter, personal communication), 
but the derivation of long HAs depends on time-consuming BAC recombineering [208, 213]. In contrast in 
the NV and OC reporter constructs short HAs allowed the use of customizable synthesized DNA blocks, in 
which the PAM sequences were mutated without an additional cloning step. Alternatively, HAs of short or 
intermediate lengths can be obtained by PCR-amplifying genomic DNA.  
 Another limitation in the production of hPSC reporter lines is the low absolute targeting efficiencies 
achieved in conventional gene targeting. With higher gene targeting efficiencies lower numbers of hPSCs 
are enough to produce reporter lines, saving time and reducing costs associated with tissue culture and 
thus encouraging the production of hPSC reporter lines. Furthermore several studies showed that high gene 
targeting efficiencies achieved with the CRISPR-Cas9 system allow omitting positive selection mechanisms 
and targeting two genomic loci simultaneously. E.g. gene editing in hPSCs and gene targeting in mouse 
oocytes have attained absolute targeting efficiencies above 1 %, which allows screening as a mean to find 
correctly targeted clones [14, 21]. Additionally, two simultaneous gene editing events were reported in 
mouse oocytes [20], and both alleles of a gene were targeted simultaneously with two large transgenes in 
HEK293 cells [276]. In the production of the NV and OC reporter lines absolute targeting efficiencies of 
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above 10-5 were achieved, which is two orders of magnitude higher than the efficiencies obtained with 
conventional gene targeting approaches in hPSCs [37]. It was previously suggested that the double nickase 
strategy is less robust than the nuclease strategy [14], but the efficiencies obtained with the double nickase 
and nuclease strategies in both NV and OC reporter production were within the same range. Thus both 
strategies allow efficient generation of reporter lines in hPSCs. Additionally it was suggested that the 
expected cut site must be in proximity of the insertion site and that the nickase pairs should be optimally 
off-set with 0-20 bp [14]. Here the OCT4-directed nickase pairs were off-set with 63 bp and still resulted in 
half of the absolute targeting efficiency of the OCT4-targeting nuclease. The two nucleases targeting 
NANOG were 110 or 41 bp downstream of the integration site, and the efficiency was tripled in the 
proximal nuclease. Hence, deviations from the optimal settings for the gRNA design are tolerated, but may 
result in minor differences in the targeting efficiency.  
Unexpectedly, sequencing of the non-targeted allele suggested that there were mutations in the seed 
sequence and the distal part of the target regions of OCT-N and OCT-DnB, respectively. At least mutations 
within the seed sequence should drastically decrease the efficiency of a CRISPR to recognize the target 
sequence and to facilitate HDR. It is puzzling that the absolute targeting efficiency for OCT-N was the 
highest among all CRISPRs. Perhaps only one of the two alleles or only some clones contained those point 
mutations within the seed sequence. Since the region containing the CRISPR target sequences are 
exchanged with the HAs during homologous recombination, it cannot be determined, whether the targeted 
alleles actually contained mutations within the CRISPR targets. If mismatches existed in the targeted alleles, 
it would suggest a low specificity of the CRISPR-Cas9 system, given the fact that HDR was still facilitated. It 
may be advantageous to empirically determine the target sequence instead of relying on the annotated 
gene sequence in order to prevent mismatches between the generated CRISPRs and the target sequences. 
The absolute targeting efficiencies in this study are 3 to 4 orders lower than the efficiencies obtained in 
gene editing in hPSCs or targeting large transgenes in mouse oocytes [14, 21], and do not allow the 
derivation of a double reporter line in a single step. Several differences in the applied strategies may 
contribute to the striking divergence in targeting efficiency. In the gene editing approach 200 bp single-
stranded oligos were used as a template instead of the around 8.5 kb pNV and pOC reporter vectors, which 
are easier to transfect. The report of efficient reporter mouse production uses the mouse oocytes, a 
completely different system than hESCs. Additionally, the Cas9 and gRNA were provided as mRNA and 
injected together with the reporter plasmid into the oocyte. Hence, the concentrations of the CRISPR 
components and the reporter plasmids could be exactly controlled, and might have been considerably 
higher than in the transfection-based production of the NV and OC reporters. Injection of lower amounts of 
Cas9 and gRNA were shown to decrease the efficiency of gene targeting dramatically [21]. 
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Proper optimization of the developed CRISPR-Cas9-based strategy for hPSC reporter derivation may narrow 
the gap between the observed absolute targeting efficiencies. As mentioned above, mismatches between 
the generated CRISPRs and the genomic targets should be prevented. Furthermore optimizations of the 
transfection and positive selection procedures may increase in the targeting efficiency [208]. Also 
identifying and changing to another culture system that allows a higher clonal efficiency than the MEF 
system may help [159]. These optimizations may increase the absolute targeting efficiency sufficiently to 
allow multiplexed genome engineering or even omission of positive selection as has been reported in other 
systems. E.g. this would save researchers months of work, whenever it is necessary to create a hPSC model 
with multiple genomic modifications, such as double reporter lines or conditional knockouts. 
 Low targeting specificity of the CRISPR-Cas9 system is a major concern. Previously off-target sites 
with up to 5 mismatches to the target sequence were affected, though the mutation rate typically was 
lower at sites with mismatches [241, 250-252]. These studies showed that the PAM and seed sequence 
were more sensitive to mismatches than the 5´ part of the target sequence. Mutations at off-targets were 
anticipated in the production of NV and OC reporters, since off-targets with no mismatches or single 
mismatches in the 5´ end existed for all applied CRISPRs. Better target regions did not exist due to NANOG 
and OCT4 pseudogenes that have a high degree of sequence similarity to the region around the NANOG and 
OCT4 stop codon. However, the previously reported high off-target activity of the CRISPR-Cas9 system was 
not observed with a T7 endonuclease-based mutation detection assay. Both in a pilot assay in HEK293 cells 
and in the NV and OC reporter lines no mutations were determined at off-target sites, except at one site 
that was perfectly complementary to the on-target site. Since the on- to off-target ratio may increase at low 
CRISPR concentrations [251], these results may suggest that the concentrations of the CRISPR components 
have been low in the cells. As previously mentioned a low concentration of CRISPR components also 
reduces the on-target cleavage efficiency [20, 21, 250, 251] and may partly explain the comparatively low 
absolute targeting efficiency in the NV and OC reporter derivation.  
In a previous study the 3´ untranslated region of NANOG or OCT4 were targeted in mice with the CRISPR-
Cas9 system, and only the off-target with the highest sequence similarity (1 mismatch at the 5´end) were 
affected [21]. Nonetheless the high specificity of the CRISPR-Cas9 system was unexpected, and perhaps the 
detection of off-targets was hindered by limitations in the T7 endonuclease-based method. E.g. naturally 
occurring polymorphisms may have masked CRISPR-induced mutations.  
Mutations may be precisely detected by deep sequencing, but the necessity to perform deep sequencing 
would significantly increase the labour and costs associated with the use of the CRISPR-Cas9 system. A 
consensus on how to assess the off-target activity in an unbiased manner would reduce the probability that 
potentially confounding genome alterations remain unnoticed and is essential for comparisons between 
studies using the CRISPR-Cas9 system. E.g. evaluation of the effect of novel alterations to the CRISPR-Cas9 
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technology on target specificity depends on uniform and unbiased assessment strategies. Furthermore 
more knowledge on the rules governing CRISPR-Cas9 target recognition would help researchers to make an 
informed choice in the gRNA design.  
In addition to off-target effects unwanted on-target mutations are a key problem with the use of the 
CRISPR-Cas9 system. Due to the high efficiency of inducing double-strand breaks at the on-target site, both 
alleles of a gene are usually affected [20]. In the NV and OC clones in 10 out of 11 analyzed non-targeted 
NANOG or OCT4 alleles mutations were detected close to the expected CRISPR cut site. Some of the used 
gRNAs recognize sequences within the coding sequence and frame shift mutations were detected in OC 
clones that result in addition of a varying number of amino acid residues to the C-terminal of OCT4. Hence, 
these results stress the importance to locate the CRISPR cut sites outside of the coding sequence and other 
known regulatory sequences to prevent frame shift mutations or other potentially confounding effects. 
Furthermore sequencing of targeted alleles of NANOG and OCT4 show that the targeted allele can be 
protected from CRISPR-induced mutations by mutating the PAM sequences in the HAs. The PAM sequence 
should not be changed to NAG or NNGG, since these sequences can serve as alternative PAM sites [236, 
241]. 
In order to render the CRISPR-Cas9 system applicable in a clinical setting, e.g. for correction of disease-
causing mutations in hiPSCs used for autologous transplantations, a way must be found to eliminate off-
target and unwanted on-target mutations. Though mutations may not have any effects, unwanted 
alterations of the genetic material of a patient is not an option. Strategies for improvements of target 
specificity involve protein engineering of Cas9 and/or modification of the gRNA to increase the sensitivity to 
mismatches [239]. Furthermore the generation of inducible forms of the CRISPR-Cas9 system may increase 
the on-target to off-target ratio due to control of the active concentration of gRNAs or Cas9 [239]. 
Reduction of unwanted on-target effects requires a shift in the balance in DNA repair from the prevailing 
error-prone NHEJ to HDR. Inhibition of the NHEJ is probably not an option, since NHEJ is a ubiquitous DNA 
repair pathway and consequently inhibition is likely to be poorly tolerated in cells [239]. A single nickase 
may be used, which usually does not produce a double-strand break and therefore does not employ NHEJ, 
but may induce HDR [15, 19]. However, the capacity of nickases to facilitate HDR was found to be more 
variable than that of nucleases and poorly understood.  
Another issue with the CRISPR-Cas9 system is the limitations in the targeting range. 
Theoretically every 8th nucleotide can be targeted, since the only requirement is the NGG PAM sequence. 
However, the target sequence needs to be unique in the genome in order to reduce the risk of potentially 
confounding off-target effects. Especially when pseudogenes are present, like in the case of OCT4 and 
NANOG, the actual targeting range is greatly reduced. No unique CRISPR target is present close to the stop 
codon of NANOG and the potential targets close to the stop codon of OCT4 have corresponding off-targets 
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with at best a single mismatch at the 5´ end. This increases the chance of off-target effects and genomic 
instability [253, 254] and may reduce the applicability of the derived reporter lines. Similar limitations apply 
to other genetic engineering tools, and in essence cannot be solved. However, a few mismatches will usually 
exist between the target and off-targets. Increasing the targeting specificity and targeting range of the 
CRISPR-Cas9 system may enable to exploit those mismatches, due to decreasing the risk of off-target effects 
and increasing the numbers of possible targets. Ways to improve the targeting specificity are discussed 
above. The targeting range may be increased by exploiting alternative PAM sequences, by protein 
engineering of Cas9, by using CRISPR-Cas9 systems from different bacterial species, or by using the type III 
CRISPR system. The use of alternative PAM sequences was reported, though the cleavage efficiency is 
reduced and not well defined [236, 241]. The CRISPR-Cas9 systems from various species have different 
targeting requirements, e.g. the consensus PAM sequences of N. meningitides and S. thermophilus are 
NNNNGATT and NNAGAAW (W=A or T) [22]. The CRISPR-Cas9-mediated cleavage has been reconstituted in 
vitro for the systems of N. meningitides and S. thermophilus [22, 246, 320]. In contrast the type III CRISPR 
system has not been assessed in vitro [244] and is less easily converted to a genetic engineering tool, since 
DNA cleavage depends on a multiprotein complex [235]. However, the type III system is independent of a 
PAM sequence and therefore has no targeting limitations [321]. Engineering of Cas9 may also alter the 
requirements to the PAM sequence [239].  
 Reporter lines for the same factor are often characterized by varying dynamics, as exemplified by 
the previously discussed NANOG reporters that led to diverging conclusions on allelic regulation of NANOG 
[296, 299, 300]. There is not a single fail-safe way to produce reporter lines. A study contrasting various 
strategies for reporter production in parallel would enable researchers to base their choice of reporter 
design on empirical data. 
However, thorough characterization of a derived reporter is necessary to confirm its validity. Some basic 
characterization of the NV and OC reporter is still lacking. For example southern blotting is usually 
performed to confirm the correct targeting of the transgene as well as the lack of randomly integrated 
additional copies of the transgene [208]. The correct targeting of the NV and OC reporter constructs were 
confirmed by PCR-based genotyping, but the existence of randomly integrated additional copies were not 
assessed. Furthermore a normal karyotype should be confirmed for the derived reporter lines, since 
karyotypic alterations occur frequently in prolonged hPSC culture [186-188]. As previously mentioned 
further immunofluorescence analysis of the OC reporter is required to strengthen the conclusion that 
mCHERRY precisely reports the dynamics of OCT4. Additionally flow cytometry-based immunofluorescence 
analysis of NANOG and OCT4 enables quantification of the overlap with the fluorescent reporter 
expression. Alternatively flow cytometry-based sorting into cells with high and low fluorescence followed by 
RT-qPCR for NANOG and VENUS or OCT4 and mCHERRY allows quantification of co-expression. Analyzing 
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other pluripotency factors and lineage-specific markers in the sorted populations by RT-qPCR would confirm 
pluripotency of the VENUSpos or mCHERRYpos populations. 
4.2. Prospective applications of NANOG-VENUS and OCT4-mCHERRY 
reporter lines 
There are several unanswered questions and controversies in pluripotency research. The NV and OC 
reporter lines and a prospective NV-OC double reporter line may help to shed light on several topics.  
The defining characteristic of pluripotency is self-renewal and maintenance of the potential to differentiate 
into all cell types of the adult body. Since differentiation is an intrinsic characteristic of hPSCs it is important 
to ensure that cells used for pluripotency research are not spontaneously differentiated. The NV and OC 
reporters may be used as a proxy for the undifferentiated state, since NANOG and OCT4 expression in 
essence is restricted to the pluripotency state and is lost soon after the onset of differentiation [283-286]. In 
fact, many studies on pluripotency used NANOG and OCT4 reporter lines to ensure that hPSCs were not 
spontaneously differentiated [36, 37]. 
Intrinsic heterogeneity was suggested as a mechanism that permits PSCs to respond to differentiation 
signals. This hypothesis is based on the intrinsic heterogeneity in the expression of pluripotency 
transcription factors such as NANOG within PSC populations, the interconvertible nature of the distinct 
expressional states, and the increased differentiation propensity of the low-expressing cells [41, 42]. In line 
with this hypothesis is the decrease in heterogeneity in naïve pluripotency that is less prone to spontaneous 
differentiation [35, 37, 43]. However, recent studies have raised doubts about the level of NANOG 
heterogeneity in primed pluripotency; other pluripotency factors, such as OCT4, were as heterogeneously 
expressed as NANOG [296, 300]. Intrinsic heterogeneity of OCT4 in primed pluripotency in mESC has 
recently been reported [322]. FACS analyses of the NV and OC reporter lines would reveal whether distinct 
low- and high-expressing populations of NANOG and OCT4 exist or whether the expression is normally 
distributed. Prospective low and high-expressing cells could be sorted by FACS, and transcriptomic, 
epigenomic and/or proteomic analyses would confirm whether distinct signatures accompany the 
fluctuations in expression. 
Culture conditions supporting naïve pluripotency of hPSCs have only recently been discovered [37, 43]. 
Culturing hPSCs in naïve pluripotency-supporting conditions may be a key to reduce the intrinsic 
heterogeneity of hPSCs, and thereby help to develop standardized differentiation protocols for the 
derivation of clinical-grade cells for cell replacement therapies. With the OC and NV reporter lines the 
dynamics of OCT4 and NANOG expression during the conversion can be followed live under the 
fluorescence microscope. This may give valuble clues about the regulation and the role of these core 
pluripotency factors in the conversion of primed to naïve pluripotency. As discussed above the use of fusion 
Discussion 
75 
 
proteins likely allows a more precise report of NANOG and OCT4 expression levels than non-fusion 
fluorescent reporters. Therefore the NV and OC reporter lines are compatible with the analysis of dynamic 
processes. 
There are controversial findings about the interplay of the core pluripotency factors. Positive feedback of 
the core pluripotency factors NANOG, OCT4 and SOX2 on themselves and each other were proposed as a 
mechanism to establish self-renewability [291-293], but other studies suggest that NANOG is 
autorepressive and has little effect on OCT4 and SOX2 [294, 295]. A NV-OC double reporter could be 
derived by either targeting NANOG with the NV reporter construct in the OC reporter or by targeting OCT4 
with the OCT4-mCHERRY reporter construct in the NV reporter. With the double reporter the relation of 
OCT4 and NANOG dynamics could be assessed, e.g. by single-cell live imaging.  
Recently a role for OCT4 and NANOG in lineage priming was suggested. Both OCT4 and NANOG are 
supposedly required for the early specification of the endoderm lineage, while repressing ectoderm 
differentiation [24, 25, 302]. The studies agree upon the role in neural lineage repression, but diverge in 
their findings on endoderm differentiation, where either OCT4 or NANOG is implicated as a necessary 
factor. Life-cell imaging of NV and OC reporter lines would reveal the dynamics of NANOG and OCT4 
expression during endoderm differentiation. A double reporter would enable direct comparisons of NANOG 
and OCT4 dynamics in single cells.  
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5. Conclusion 
Progress in hPSC research is greatly hindered by the difficulty of performing genetic studies in hPSCs. This 
study presents a strategy for rapid production of faithful hESC reporter lines.   
Reporter plasmids were efficiently produced by assembling PCR amplifications and synthesized DNA blocks 
with Seamless cloning. This strategy was independent of restriction sites, did not leave restriction scars and 
allowed assembly of four DNA fragments in a single step. 
NV and OC reporter lines were produced by targeting NANOG and OCT4, respectively. Heterozygosity in the 
targeted genes was prevented by inserting the VENUS and mCHERRY fluorescence genes in-frame prior to 
the stop codon. An additional advantage of the strategy is the use of the endogenous 3´UTR that often 
contains regulatory sequences. Homologous recombination was facilitated by targeting a site proximal to 
the insertion site with the CRISPR-Cas9 system. Furthermore the targeting strategy involved the use of short 
HAs to allow employing synthetic DNA blocks and a promoter trap approach for positive selection. 
The absolute targeting efficiencies obtained in the derivation of NV and OC reporter lines were 1-5.7x10-5, 
which constitutes an increase of approximately two orders of magnitude in comparison to conventional 
gene targeting approaches in hPSCs. Since the targeting efficiencies were in the same range for all assessed 
CRISPR targets of both the double nickases and nucleases, it can be concluded that the CRISPR-Cas9 system 
robustly facilitates homologous recombination using large transgenes in hESCs. Furthermore deviation from 
the previously suggested optimal off-set between nickase pairs and increased distance of the CRISPR target 
to the insertion site was well tolerated, suggesting flexibility in CRISPR target design.  
The increase in absolute targeting efficiency decreases the number of cells needed for the derivation of 
genetically modified clones. Thereby the cost and time associated with the production of hESC reporter 
lines is decreased and genetic studies with a higher throughput are encouraged. The absolute targeting 
efficiencies were not sufficient to allow the derivation of a double reporter line in a single targeting step. 
The ability to target two large transgenes to specific genomic loci simultaneously would save researchers 
time, whenever it is necessary to create a model with multiple genomic modifications. Optimization of the 
transfection and positive selection procedures, as well as prolongation of the HAs are obvious options that 
may further increase the absolute targeting efficiency of the developed strategy.  
A relative targeting efficiency of in average 86 % was achieved. High relative targeting efficiencies decrease 
the number of clones that need to be screened to find a correctly targeted clone. The T2A self-cleaving 
peptide was shown to allow multicistronic expression from the endogenous promoter, though around 6 % 
of the protein remained uncleaved. The promoter trap approach for positive selection probably contributed 
to the exceptionally high relative targeting efficiency. The promoter trap approach is restricted to factors 
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expressed in pluripotency. It remains to be assessed whether the use of the CRISPR-Cas9 system itself 
increases the relative targeting efficiency by alerting the DNA repair system to the insertion site. 
Despite low qualities of the CRISPR targets, mutations were only detected in a single off-target locus that 
was completely homologous to the target. Hence, the previously reported low specifity of the CRISPR-Cas9 
system cannot be confirmed. 
At the on-target sites concomitant mutations were observed in 10 out of 11 analyzed clones. In order to 
prevent potentially confounding mutations in the non-targeted allele, it is necessary to place the CRISPR 
target sites outside coding regions or regulatory elements. For prospective therapeutic applications of the 
CRISPR-Cas9 system unwanted mutations must be prevented, which necessitates a shift in the balance from 
NHEJ to HDR. Mutations in the targeted allele were prevented in the OC reporter by mutating the PAM 
sequences in the HA. The use of customizable synthetic DNA blocks as HAs allowed simple generation of the 
point mutations. The introduction of point mutation may be preferable to indel mutations of varied lengths 
induced by the CRISPR-Cas9 system.  
The NV reporter faithfully reports the dynamics of NANOG expression. This may be attributable to the use 
of a fusion construct, since it was previously shown that the stabilities of NANOG and NANOG fusion 
proteins are identical. Precise reporter lines change the resolution of studies of important developmental 
factors, e.g. fluctuations or the precise timing in the decline of a factor can be determined. Further analyses 
of the NV and OC reporter lines are necessary to assess their characteristics. It is anticipated that the NV 
and OC reporter lines and a prospective NV-OC double reporter line will be valuable tools for analyzing the 
dynamics of NANOG and OCT4 in pluripotency and early endodermal development. 
In conclusion, it is expected that genetic studies in hPSCs will become less laborious due to the simplicity, 
high efficiency and broad applicability of the CRISPR-Cas9 system. The developed strategy for the derivation 
of reporter lines is expected to be generally applicable for the insertion of large transgenes in hPSCs. 
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Abbreviations 
Aß: amyloid-beta-peptide 
BAC: Bacterial artificial chromosome 
bFGF: basic fibroblast growyh factor 
bp: Base pair(s) 
Cas9: CRISPR-associated 9 
Cas9n: Cas9 nickase 
CRISPR: Clustered regularly interspaced short 
palindromic repeat 
dCas9: dead Cas9 
DE: Definitive endoderm 
DMEM: Dulbecco´s Modified Eagle Medium  
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
ECM: extracellular matrix 
ESC: Embryonic stem cell 
EST: Embryonic stem cell test 
FACS: Fluorescence-activated cell sorting 
FBS: Foetal bovine serum 
gRNA: GuideRNA 
HA: Homology arm 
HDR: Homology-directed repair 
HEK293 cells: Human Embryonic Kidney 293 cells 
hESC: Human embryonic stem cell 
hiPSC: Human induced pluripotent stem cell 
hPSC: Human pluripotent stem cell 
ICM: Inner cell mass 
indel: Insertion and deletion mutations 
iPSC: Induced pluripotent stem cell 
IRES: Internal ribosomal entry site 
kb: Kilo base pair(s) 
KO-DMEM: KnockOut DMEM  
MEF: Mouse embryonic fibroblasts 
mESC: Mouse embryonic stem cell 
ml: Mililiter 
µl: Microliter 
NAN-Dn: Double nickase targeting NANOG 
NAN-N: Nuclease targeting NANOG 
N.: Neisseria 
NHEJ: Non-homologous end-joining 
nm: Nanometer 
nM: Nanomolar 
NV: NANOG-VENUS 
NV-Dn: NV clone produced with double nickases 
NV-N: NV clone produced with nuclease 
PBS: Phosphate buffered saline 
PBST: PBS with 0.5 % Tween20 
PBS-TX100: PBS containing  Triton X-100 
OC: OCT-mCHERRY 
OC-Dn: OC clone produced with double nickases 
OC-N: OC clone produced with nuclease 
OCT-Dn: Double nickase targeting OCT4 
OCT-N: Nuclease targeting OCT4 
PAM: Protospacer adjacent motif 
PCR: Polymerase chain reaction 
pNV: NV reporter plasmid 
pOC: OC reporter plasmid 
PSC: Pluripotent stem cell 
RNA: Ribonucleic acid 
ROCK: p160-Rho-associated coiled-coil kinase 
RPMI: Roswell Park Memorial Institute Medium 1640 
SDS: Sodium dodecyl sulfate 
S.: Streptococcus 
TALEN: Transcription activator-like effector nuclease 
UTR: Untranslated region 
wt: Wild type 
ZFN: Zinc finger nuclease 
 
 i 
 
Appendix: DNA block sequences 
OCT4 3´ homology arm 
5´CTTGACGAGTTCTTCTGAGGTGCCTGCCCTTCTAGGAATGGGGGACAGGGGGAGGGGAGGAGCTAGGGAAAGAAAACCTGAAG
TTTGTGACAGGGTTTTTGGGATTAAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGGGGAGTTTGGG
GCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTCTTGATTTTAATCCCACATCATGTATCACTTTTTTCTTAAATAAAGAAGCCT
GGGACACAGTAGATAGACACACTTATCTTGGTTTGTCCTTCAGTTACTGAGGTAGGGATGGGAATATCCAATGCTCATACCCAAGTGA
CCCTGAAACTAAGGTGCCATTTACACTCCTTAAGGTCACACAACATCAGAGGGAGAGCTGGGATTGCAGCCAAGTTTATTTGTACAG
GGCCCTGTGATAGGCTAGTTCCCAAAAGCCTGTGATGCAAGAACTTTTGCCCATAGACTCAGTCACCATGTAGCTGTTACCTGTTCAG
AGCTGGCTTTTTGCTTTCCCACCCTACTCTGGAATTCTTAAATGGCTTTATACTTAGAAATCATCTTATTTCTGTTGAACCTAGATCACCC
CAACCAGAAACTTCTATTAATACTTTGTGCTTTCTTGATACCAGGGTCTATTTGGTTTCCACTTAAGGTTTTTGCATACTCTGCCCATAAG
TGACTCATTAGTTACTCAAGTTTTATTCCTGGCTAGGGATAACAGGGT 3´ 
NANOG 5´ homology arm 
5´GATCCCTTCAGGAATAAAAGTTAGCAATATACTTTGATTCAAAGTACCTCTGTATTATGAATATTTTACAATTTCTATCATTTTTTCCTGC
AGGTGAAGACCTGGTTCCAGAACCAGAGAATGAAATCTAAGAGGTGGCAGAAAAACAACTGGCCGAAGAATAGCAATGGTGTGAC
GCAGGTAACAGGAAACTTCATTCTGTTCTTTCCTTTCAGTGATCTTTCAATCTTGTCCATCCCTGAAACACACAACTCCAGTCACAGAC
AGTTCTGGTTGTCCTTGTACCCTTTCTGTTAATCCCTCCTTCTCTTTCAGAAGGCCTCAGCACCTACCTACCCCAGCCTTTACTCTTCCTA
CCACCAGGGATGCCTGGTGAACCCGACTGGGAACCTTCCAATGTGGAGCAACCAGACCTGGAACAATTCAACCTGGAGCAACCAGA
CCCAGAACATCCAGTCCTGGAGCAACCACTCCTGGAACACTCAGACCTGGTGCACCCAATCCTGGAACAATCAGGCCTGGAACAGTC
CCTTCTATAACTGTGGAGAGGAATCTCTGCAGTCCTGCATGCAGTTCCAGCCAAATTCTCCTGCCAGTGACTTGGAGGCTGCCTTGGA
AGCTGCTGGGGAAGGCCTTAATGTAATACAGCAGACCACTAGGTATTTTAGTACTCCACAAACCATGGATTTATTCCTAAACTACTCCAT
GAACATGCAACCTGAAGACGTGGGAGGTAGTGGCGGTAGCGGC 3´ 
Bold font marks the sequences that are immediately upstream or downstream of the homology arms in the reporter 
plasmids (overhangs necessary for Seamless cloning), italic and bold font mark the additional four codons of the linker 
sequence introduced via the DNA block, and red coloured nucleotides diverge from the annotated OCT4 sequence 
(mutated PAM sites in the OCT4 3´ homology arm to prevent CRISPR-induced mutations in the targeted allele). 
 
